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Abstract 
 
Dynorphin A 1-17 [Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-
Asn-Gln] is an endogenous opioid peptide. It is widely distributed in blood and CNS tissue and 
exhibits a high affinity to the kappa (κ) opioid receptors and binds with less affinity to both delta 
(δ) and mu (µ) opioid receptors. This peptide has been found to show both antinociceptive and 
analgesic effects within the central nervous system. Dyn A is also involved in the body’s immune 
response, in addition to control of heart rate, blood pressure, body temperature and feeding 
behavior. However, upregulation of Dyn A due to disease states has been shown to cause 
nonopioid activity such as hyperalgesia, allodynia, and excitotoxicity. In addition, altered levels 
of the neuropeptide have been linked to neurological disorders, including Alzheimer’s and 
Parkinson’s disease. Capillary electrophoresis is a powerful technique that can achieve high-
efficiency separations of charged analytes. However, CE has limited use for the analysis of basic 
proteins and peptides, due to their adsorption onto the inner surface of the fused silica at pHs below 
their pI. This adsorption can lead to a loss of efficiency, irreproducibility of migration times, and 
peak tailing. This thesis describes the separation of dynorphin A 1-17 and its key metabolites using 
fused silica capillaries coated with positively charged polydiallyldimethylammonium chloride 
(pDDA) and pDDA stabilized gold nanoparticles modified capillaries. The coating material 
minimized unwanted adsorption of the positively charged peptides onto the surface of the fused-
silica capillary.  
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The studies with capillary electrophoresis were performed using UV detection at 214 nm. 
However, the detection limits are too high to determine endogenous concentrations of these 
bioactive peptides in brain microdialysis samples. To improve the detection limits, while still 
maintaining small sample volume requirements, the development of glass and 
glass/polydimethylsiloxane microchip electrophoresis (ME) system with fluorescence detection is 
described. Several fluorescence tags were evaluated including the fluorescent probe, fluorescein 
isothiocyanate, and the fluorogenic probe, naphthalene-2,3-dicarboxaldehyde with sodium 
cyanide, which produces a fluorescent 1-cyanobenz[f]isoindole (CBI) derivative. The ME-LIF 
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 The endogenous opioid peptide dynorphin A (Dyn A) is a 17-amino acid polypeptide [Tyr 
- Gly - Gly - Phe - Leu - Arg - Arg - Ile - Arg - Pro - Lys - Leu - Lys - Trp - Asp - Asn - Gln]. The 
peptide was first isolated from porcine pituitary by Goldstein and co-workers1. It is widely 
distributed in blood and CNS tissue and exhibits a high affinity to the kappa (κ) opioid receptors. 
It also binds with less affinity to both delta (δ) and mu (µ) opioid receptors. Dyn A has been 
reported to show both antinociceptive and analgesic effects within the CNS. It is involved in the 
body’s immune response as well as control of heart rate, blood pressure, body temperature and 
feeding behavior. However, upregulation of Dyn A due to pathophysiological states has been 
shown to cause nonopioid activity such as hyperalgesia, allodynia, and excitotoxicity. In addition, 
altered levels of the neuropeptide have been linked to neurological disorders, including 
Alzheimer’s and Parkinson’s disease.  
 This thesis explores the use of various electrophoresis separation methods, mainly capillary 
electrochromatography and microchip electrophoresis, for the separation of Dyn A (1-17) and its 
metabolites.  
  
1.2 Chapter summaries 
1.2.1 Chapter two 
This chapter provides an overview of the classification of opioid peptides and their 
receptors. It also provides a more detailed look at the CNS distribution of the opioid peptide Dyn 
A and its metabolism. In addition, this chapter provides a general summary of some of the 
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pharmacological effects of Dyn A and a description of reported pathophysiological effects that are 
caused by abnormal levels of the neuropeptide. 
A review of some of the different analytical methods that have been reported for the 
separation and detection of Dyn A and its metabolites are also provided in this chapter, including 
liquid chromatography, micellar electrokinetic chromatography (MEKC) aqueous capillary 
electrophoresis (CE) and nonaqueous CE, that are coupled with different detection methods such 
as  ultraviolet (UV), fluorescence and mass spectrometry (MS). 
 
1.2.2 Chapter three 
Chapter three is a review of approaches and strategies reported for the separation of protein 
and peptides by CE, microchip electrophoresis and capillary electrochromatography (CEC).  The 
primary focus of the chapter is on the theory, classification, and materials used for CEC separation 
and applications of these techniques to protein and peptides, to improve both resolution and 
efficiency of protein and peptides analysis.  
  
1.2.3 Chapter four  
 This chapter describes the development of a polydiallyldimethylammonium chloride-
stabilized gold nanoparticle-coated (pDDA-GNPs) capillary for an electrochromatography based 
separation of the basic peptide Dyn A (1-17) and seven of its fragments. The pDDA-GNPs coated 
capillary was used to minimize undesirable adsorption of positively charged peptides onto the 
surface of ionized fused-silica capillary. A range of CEC separation parameters including capillary 
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length, applied electric field strength and concentration of background electrolyte were evaluated 
for the peptide separation of fragments of Dyn A. Finally, the CEC pDDA-GNPs coated capillary 
was applied for separation of tryptic peptide fragments of dynorphin A 1-17. 
  
1.2.4 Chapter five  
 Dynorphin A and its metabolites are found at very low concentrations. CE-UV can be used 
to provide quantitive data for higher concentration samples of these opioid peptides. However, in 
order to achieve the limits of detection necessary for the detection of dynorphin and its metabolites 
in microdialysis samples, a more  sensitive method, such as fluorescence, must be employed.  
Therefore the compounds were derivatized with naphthalene-2,3-dicarboxaldehyde and sodium 
cyanide to produce fluorescent 1-cyanobenzoic[f]isoindole derivatives. The products were 
separated and detected by CEC and ME with laser-induced fluorescent detection (LIF). Chapter 
five provides the results of the development of a capillary and microchip LIF system for the 
separation of dynorphins.  
 
1.2.5 Chapter six 
This chapter summarizes the research presented in this thesis, and provides a discussion of 
future directions for the determination of dynorphin A and other neuropeptides in biological 






The appendix provides the result of in situ perfusion studies that were carried out on 
Sprague Dawley® rats for investigating the activity of Dyn A(1-6) on the blood brain barrier. It 
was previously observed that this peptide increased the permeability of the BBB using a cell 
culture model. In these studies, the effect of Dyn (1-6) on the permeability of 14C-mannitol at the 
blood-brain barriers (BBB) in situ was investigated. The in situ perfusion was used to compare the 
effect of opioid peptide Dyn A(1-6) to control, and to that of a scrambled peptide (GLYRFG). A 
hypothesis for the activity of Dyn A(1-6) for changes in BBB permeability is also provided. 
 
1.3 References  
1. Goldstein, A.; Fischli, W.; Lowney, L. I.; Hunkapiller, M.; Hood, L., Porcine pituitary 
dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc. 































The opioid system is composed of several peptides and various types of receptors. Both 
opioid peptides and their receptors are widely distributed in the central (CNS) and peripheral 
nervous systems (PNS)1-2. They act as neurotransmitters and neuromodulators3. They also regulate 
main physiological states that include cardiovascular 4 and endocrine balance5. 
 
2.1.1 Opioid peptide 
Opioid peptides are formed by proteolytic cleavage of three protein precursors. The protein 
proopiomelanocortin (POMC) is the precursor of β-endorphin, preproenkephalin (PENK) is the 
precursor of Met-enkephalin (Met-ENK) and Leu-enkephalin (Leu-ENK), and preprodynorphin 
(PDYN) is the precursor of dynorphin A, dynorphin B and neoendorphin6 [Figure 1]. Opioid 
peptides range in length from 5-31 amino acids. They share a common N-terminal tetrapeptide 
sequence of Tyr-Gly-Gly-Phe that is essential for binding to the opioid receptor’s “message 
domain”. However, these peptides differ in the C-terminal residues or ”address domain” [Figure 
2]. This effects the affinity of these peptides to the opioid receptor and their subtypes7. For 
example, the neuropeptide, nociceptin, (orphanin  FQ) is produced from the precursor pronocicptin 
(PNOC) and lacks the N-terminal Tyr. Thus, it has a very low affinity to opioid receptors and acts 
on a different receptor8. Opioid peptides, such as enkephalins and dynorphins, are found in various 
regions of the brain such as the hypothalamus, posterior pituitary, striatum, substantia nigra,  
hippocampus, and amygdala9. Dynorphins, in addition to being in the brain, are also present in 
high amounts in the interneurons of the spinal cord10-11. Opioid peptides are also produced in 
nonneuronal cells, such as the immune and endocrine cells12. Endogenous opioid peptides help 
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regulate (balance) the body’s homeostasis, by acting as neurotransmitters and hormones, as they 
influence several physiological and pathological states. 
   
2.1.2. Opioid receptors 
The family of opioid receptors includes the µ, δ, and κ receptors. These are all considered 
part of what is known as the “classical” opioid receptors, based on the classification of the 
antagonist effect of naloxone on opioid receptors. Nociceptin receptors (NOR) show activity to 
nociceptin and are classified as a non-opioid member of the opioid receptors family. This 
classification is based on the shared structural similarities and location of NOR to the classical 
opioid receptors but the difference in the activity of naloxone to the NOR (inactive)13.  Subtypes 
of classical opioid receptors have been identified based on their pharmacological response; this 
includes the µ1, µ2 and µ3 for µ opioid receptors, δ1 and δ2 for δ opioid receptors, and κ1a, κ1b, κ2a, 
κ2b, κ3 for the κ opioid receptors 
13-14. 
The opioid receptors µ, δ, and κ all belong to a family of receptors called the G-protein-
coupled receptors (GPCR) that are also known as the seven-transmembrane domain receptors. All 
three types of opioid receptors share high structural similarities, mainly at the transmembrane 
domains 2, 3, 7 and the 1st and 2nd intracellular loops of the GPCR15. This explains the ligand 
selectivity and high affinity to one type of opioid receptors and lower affinity to other types of 
opioid receptors. Ligands of the GPCR cause activation of the GPCR via coupling with Gi/Go 
proteins of receptors and which activation leads to inhibition of adenyl cyclase (AC), thereby 
reducing production of cyclic adenosine monophosphate (cAMP). This reduces calcium ion influx 




















G protein-coupled inwardly-rectifying potassium channels (GIRK)16 causing efflux of potassium 
ions. This induces membrane hyperpolarization of the neurons causing inhibition of neuronal 
release of excitatory neurotransmitter [Figure 3]17-18.  Table 1 shows a summary of the opioid 




Table 1: Summary of differences of opioid receptors and ligands. [CTAP: DPhe-Cys-Tyr-DTrp-
Arg-Thr-Pen-Thr-NH2, CTOP: 
DPhe-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2, nor-BNI: 
nor-binaltorphimine].   
  
2.2 Dynorphin A 
 The opioid peptide dynorphin (Dyn) was named based on the prefix “Dyn” from the Greek 
word dynamic (power) and the suffix “orphin” indicating its opioid nature24. It was first isolated 
from the porcine pituitary in 197525. After its discovery, further studies have shown that Dyn is 
widely distributed within the CNS, with the highest concentrations of the neuropeptide found the 
posterior lobe of the pituitary. This is followed by the hypothalamus then striatum, then midbrain,  
 µ δ  κ NOR 




endomorphin-2 19  
Leu-enkephalin, 
Met-enkephalin 
Dynorphin A Nociceptin 
Selective antagonist  CTAP, CTOP20 Naltrindole21 Nor-BNI 22 LY294009423  
Antagonist effect of 
naloxone 








Figure 3: Effect of the opioid peptide on neuronal cells by acting on GPCR and NMDA receptors 





hippocampus, medulla-pons and spinal cord followed by cortex and then the cerebellum27. Dyn A 
(1-17) is composed of 17 amino acid residues Tyr1-Gly2-Gly3-Phe4-Leu5-Arg6-Arg7-Ile8-Arg9-
Pro10-Lys11-Leu12-Lys13-Trp14-Asp15-Asn16-Gln17. The neuropeptide has the highest affinity to the 
κ opioid receptor and shows lower affinity to the δ, and a lesser extent to the µ receptors28. The 
primary structure of Dyn can be divided into two domains. The first is the messenger domain that 
corresponds to the N-terminal tetrapeptide of Dyn (Y1G2G3F4). These four amino acid residues are 
essential for binding to the opioid receptors. The second domain is the address domain that 
corresponds to the C-terminal29. The address domain affects the selectivity of the peptide to the κ 
opioid receptor.  
The structural extension of the neuropeptide sequence Leu-ENK YGGFL5 (Ki µ:6.9 nM, 
δ:0.37 nM, κ: 93.65 nM) with the addition of an Arg residue YGGFLR6, leads to a 30 fold increase 
in affinity to the κ receptors (Ki κ: 2.88 nM) and a decrease in affinity to the δ opioid receptors (Ki 
δ: 1.04 nM) compared to Leu-ENK30.  Addition of another Arg residue at position seven has been 
reported to show a 14-fold further enhancement of the affinity of the Dyn peptides to the κ receptor 
(Ki κ: 0.21 nM)
30-31. Further structural extension of the C-terminal of the Dyn peptide did not 
distinctly improve affinity or selectivity to the κ receptors. Although longer chain fragments of the 
Dyn peptides such Dyn A (1-13) (Ki κ: 0.23 nM) and Dyn A (1-17) (Ki κ: 0.37 nM) provide 
extended activity, this may be due to the longer peptide chain show longer stability 30-32. Table 2 
shows the in vitro experimental Ki values to the opioid receptors (µ, δ, and κ) of various ligands. 
Aside from opioid receptors, Dyns and their fragments have been reported to bind to non-opioid 







Table 2: Ligands and opioid receptors Ki values. Table from Mansour et. al 30  
    
2.2.1 Dynorphin metabolism 
 Dyn A can undergo metabolism by various proteolytic enzymes in the brain, spinal cord, 
cerebrospinal fluid (CSF) and blood. Enzymatic cleavage of Dyn A and its fragments can produce 
metabolites that can also be active at opioid receptors or produce fragments that may not bind to 
 
Opioid receptor (Ki values)  
 µ (nM) δ (nM) κ (nM) 
Leu-ENK 6.19 0.37 93.65 
Met-ENK 1.8 0.45 47.44 
Dyn A (1-6) 1.88 1.04 2.88 
Dyn A (1-7) 1.80 2.71 0.21 
Dyn A (1-8) 2.56 1.17 0.45 
Dyn A (1-9) 2.62 1.47 0.13 
Dyn A (1-13) 4.14 5.56 0.23 
Dyn A (1-17) 2.64 1.29 0.37 
Dyn A (1-32) 6.87 3.34 3.08 
β-Endorphin (1-27) 5.31 6.17 39.82 
β-Endorphin (1-31) 3.37 5.02 32.70 
Morphine 7.48 302.15 52.65 
Naloxone 0.92 18.76 2.09 
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the opioid receptors but may bind to various other types of receptors within the body. 
Aminopeptidase is known to cleave the N-terminal Tyr group of Dyn, producing a des-tyrosyl 
fragment that shows a low affinity for the opioid receptors, but shows a high affinity to other 
receptors (mainly the NMDA receptor). C-terminal enzymatic cleavage of the peptide amino acid 
chain by carboxypeptidase has also been shown in both blood and CSF34-35. Other enzymes that 
have been reported to act on Dyn A by cleaving peptide bond at different regions of the peptide 
chain include angiotensin converting enzyme (Phe4-Leu5), dynorphin A-processing enzyme (Arg6-
Arg7 and Ile8-Arg9)36, and finally, dynorphin A-converting enzyme that has been described to 
convert Dyn A(1-17) to dynorphin A(1-6) and Leu-ENK in the human spinal cord37. 
 In vitro studies on the metabolism of the dynorphin A (1-13) in blood have shown that the 
peptide has an extremely short half-life (t1/2) of less than 1 minute
34, 38 compared that of Dyn A (1-
17), with a t1/2 of  approximately 180 minutes
35. The longer stability of Dyn A (1-17) is believed 
to be due to the C-terminal amino acid residues that protect the peptide from enzymatic 
degradation.  
Chou et.al.35 investigated the biotransformation of both Dyn A(1-17) and Dyn A(1-13) in 
human blood using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS). 
The peptides were incubated in a human blood, and at various time points, small portions of the 
sample mixture were collected and analyzed. Chou reported major metabolites of Dyn A (1-17) in 
blood include Dyn A (2-17), Dyn A (7-17), Dyn A (8-17) and Dyn A (9-17). The major metabolites 
of Dyn A (1-13) include Dyn A (1-12) and Dyn A (2-12) and Dyn A (4-12). Table 3 presents a 









Enzyme  Cleavage site Reference  
Dyn A (2-17) 
Aminopeptidase M Tyr1-Gly2 
39 
Dyn A (2-12) 34 
Dyn A (1-12) Carboxypeptidase Leu12-Lys13 34-35 
Dyn A (1-6) Dynorphin converting enzymes Arg6-Arg7 37 
Dyn A (1-10) Angiotensin converting enzyme Pro10-Lys11 38 
Dyn A (1-8) Dynorphin processing enzymes Ile8-Arg9 36 
Dyn A (1-4) Angiotensin converting enzyme Phe4-Leu5 34 
Dyn A (1-8) Carboxypeptidase E Ile8-Arg9 40 
 
Table 3: Summary of produced fragments of Dyn A by enzymatic cleavage. 
 
2.2.2 Pharmacological effects of dynorphin 
The pharmacological effects of Dyn and its metabolites are not fully understood. This could 
be due low endogenous levels and the rapid metabolism of the neuropeptides by a wide range of 
enzymes in the CNS and plasma34. Besides its effect on the nervous system, several of these 
peptides have been found to serve multiple regulatory functions such as cardiovascular regulation, 
temperature regulation, and hormonal balance. 
 
2.2.2.1 Analgesic effects 
Similar to the classic example of an opioid receptor agonist, animals studies have shown 
the analgesic property of Dyn 41-42.  Several research groups have reported that low-dose intrathecal 
injections (IT) of Dyn A (1-13) in human cancer patients as well as rat and mice models, produced 
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an analgesic effect with a potency effect similar to morphine42-45. However, high doses of Dyn 
given IT to rats have been shown to produce neurotoxic effects that include hindlimb paralysis and 
enhanced sensitivity to sensory stimuli46-48. The neurotoxic effects are suggested to be due to the 
non-opioid activity at other receptors, since the same adverse effects occur with an IT injection of 
Dyn derivatives that lack the N-terminus Tyr residue. Nerve injury and peripheral inflammation 
have been found to lead to an upregulation of spinal Dyn A production and are associated with 
chronic neuropathic pain11. The effect of Dyn in the brain has been reported to be opposite to that 
in the spinal cord. Intracerebroventricular injection (icv) of Dyn in the brain of mammalian animal 
models has produced no analgesic effect.  
  
2.2.2.2. Interaction of dynorphin with nonopioid receptors 
Several research articles have reported that under physiological concentrations, dynorphin 
binds with high affinity to the κ opioid receptors. However high levels of Dyn production due to 
pathophysiological states, such as trauma or spinal injuries, cause the peptide to act on nonopioid 
receptors such as NMDA and AMPA leading to neurotoxic effects49. Hauser et.al 50 performed in 
vitro toxicity studies of fragments of Dyn A by looking at their interaction with expressed κ opioid 
and NMDA receptors on mouse spinal cord neurons. They found that concentrations of Dyn of 
1mM or greater led to significant neuronal loss. Neuronal loss was also reported for dynorphin 
fragments. Dyn A (1-17) was found to be the most toxic, this was followed by Dyn A(1-13), and 
then Dyn A(2-13) and Dyn A(13-17). In contrast, Dyn A (1-11) and Leu-ENK were found not to 
cause neuronal death. The toxic effects of the Dyn neuropeptides is believed to be mediated by 




2.2.2.3 Cardiovascular effects 
The effect of the Dyn A on both blood pressure and heart rate has been investigated by 
several research groups52-54. The effect is seen in both the CNS and PNS, and affects both opioid 
and nonopioid receptors32, 55. Studies have shown that the effect of the neuropeptides on the 
cardiovascular system (CVS) appear to depend on the site of administration and the state of 
consciousness of the animal model studied. Injections of Dyn A into specific regions of the brain 
in anesthetized rats was reported to cause both hypotension and bradycardia. These effects were 
blocked by the naloxone, indicating that the activity of Dyn is mediated by opioid receptors27, 52. 
Stimulation of opioid receptors at the presynaptic nerve terminal could lead to inhibition of 
norepinephrine release and cause the observed CVS effects. However, with the IV administration 
of Dyn to awake animals, this has been reported to induced a hypertensives effect, due to 
stimulation of the nonopioid receptors, that can cause a blockade of norepinephrine reuptake27, 32, 
56.  
  
2.2.2.4 Temperature and hormonal effects 
Dyn has been found to cause a small hyperthermic effect when administered alone. 
However, when it was administered after an IV injection of morphine, the Dyn was found to 
potentiate the hypothermic effect of morphine57. The concentrations of the Dyn within different 
regions of the brain was found to be altered by body temperature. Morley et.al. 58 found lower 
levels of Dyn in the hypothalamus of rats that were subjected to a two-hour exposure to a 
temperature of 4°C. Thus suggesting that the peptide has a neuromodulatory effect, by acting as a 
feedback system for controlling body temperature57. 
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Dyn has been reported to affect the level of several hormones, such as prolactin59-60 and 
luteinizing hormone61. It has also been reported to suppress the release of oxytocin in lactating 
rats62. 
 
2.2.3 Dynorphin and neurodegenerative disorders 
At normal concentrations in the body, Dyn is involved in multiple regulatory functions. 
However, abnormal levels of the neuropeptide are believed to be linked to various neurological 
disorders. Dyn is thought to be related to the pathology of Alzheimer disease. In rodents, it was 
found that Dyn production is upregulated with age, and the neuropeptide induces 
neurodegeneration and cognitive impairment63.  Postmortem brain samples of human patients that 
have shown symptoms of Alzheimer disease, exhibit elevated Dyn levels64. It is proposed that one 
of the contributions to the disease may be elevated levels of Dyn acting through nonopioid 
receptors64. 
 
2.2.4 Dynorphin effect on the reward pathway 
It has been reported that the administration of drugs of abuse (e.g. cocaine), leads to an 
increase in dopamine levels in the brain. The κ opioid receptors can be found in the presynaptic 
terminal of the synapses of the mesolimbic dopamine neurons 65-66. The activation of the κ opioid 
receptors by Dyn or synthetic agonists such as U-69593 and bremazocine can inhibit dopamine 
release in the striatum67. In contrast, the κ opioid receptors antagonists such as nor-binaltorphimine 
(nor-BNI) cause stimulation of dopamine release68. Chronic administration of drugs of abuse can 
lead to upregulation of Dyn production in the brain, were the neuropeptide has a neuroprotective 
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effect from drug-induced high levels of dopamine69. Zang et.al. 70 investigated the effect of Dyn 
A(1-17) on the cocaine-induced increase in dopamine levels in the caudate putamen of mice. They 
were able to show that there was a decrease in dopamine levels when Dyn A(1-17) was directly 
infused into the caudate-putamen in the animal. They also showed that pre-injection of mice with 
nor-BNI blocked the effect of Dyn and increased dopamine levels. These results supported the 
hypothesis that the activation of the κ opioid receptors can modulate the effect of cocaine. 
 
2.3. Analytical methods for determination of dynorphin 
2.3.1 Chromatographic methods 
2.3.1.1 Liquid chromatography (LC) with ultraviolet absorbance detection 
One of the oldest articles describing the use LC for analysis and separation of Dyn A(1-
17) was by Seyfried and Tobler71. They developed a chromatographic method for the separation 
of some of the N- and C-terminal fragments of Dyn A(1-17) produced by the incubation with 
homogenized striatum and spinal cord of Wistar rats. The LC methods involve the use of a C-8 
column with 5µm particles (25 cm × 4.66 mm i.d.). Samples were analyzed with one of the 
following two gradients. Gradient elution method I ( phase A: 60% acetonitrile): t = 0−21 min 
(0−34% B), then t = 21−31 min (34% B), and finally t= 31−60 min (100% B). Gradient method II 
was performed for higher resolution of short non-Tyr containing fragments, the following mobile 
phase gradient was used (gradient elution method II): t = 0−12 min (0 – 22% B), then t = 12−22 
min (22% B), and finally t = 22−60 min (100% B). With both methods, the flow rate was constant 
at 1 mL/min. Ultraviolet (UV) absorbance detection was used to detect the eluted neuropeptides 
at 210 nm.  
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2.3.1.2 LC with fluorescence detection 
 
Fluorescence detection can provide a more sensitive method for the determination of Dyns 
and other neuropeptides. Kai, M et.al.72 reported a pre-column fluorescence derivatization method 
for selectively derivatized peptides containing tryptophan residue at the N-terminus of the peptide. 
The N-terminal primary amine of a Trp-containing peptide can react with glyoxal [Figure 4] if the 
mixture is heated to 100 °C for 30 min. The fluorescent product was detected at an excitation 
wavelength (λEx) of 275 nm and an emission wavelength (λEm) of 465 nm [Figure 5]. One example 
that shows an application of this derivatization method was the LC analysis of the tryptic digest of 
Dyn A(1-17). The tryptic digest produced several N- and C-terminus products that can be detected 
with LC/UV. However, only one peptide fragment (Trp-Asp-Asn-Gln) was detected after sample 
derivatization with glyoxal by the LC/fluorescent detection system because of the selectivity of 
the fluorescence reagent for the  N-terminus Trp. The chromatographic method used a 5µm particle 
size TSKgel ODS-80Tm column (15 cm × 4.6 mm i.d.). An isocratic mobile phase that consisted 
of 60% 20 mM phosphate, 23% acetonitrile and 17% methanol was employed at a flow rate of 0.8 
mL/min.   
Another LC/fluorescence method was reported for the determination of the concentration 
of various N-terminal tyrosine peptides including Leu-ENK, Met-ENK, Dyn A(1-6), Tyr-Gly-Gly-
Phe and Tyr-Arg. This approach involved pre-column fluorescent derivatization of the N-terminal 
tyrosine residue with a borate solution (pH 8.5) containing hydroxylamine and cobalt(II) ions. 
Analytes were separated on a reverse phase 5µm particle size TSKgel ODS-120T (15 cm × 4.6 
mm i.d) colum. The gradient elution was from 2-26% of ACN in an aqueous solution of 
tetrabutylammonium chloride. The fluorescent products (structure unknown) were detected at λEx 
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of 330 nm and λEm of 440 nm. The method was reported to be both sensitive and selective for the 
tested peptides, however the estimated yield for fluorescent derivatization of the two neuropeptides 
Leu-ENK, Met-ENK was 55%. They reported a limit of detection (LOD) of 1.5 pmol based on a 
signal-to-noise ratio of 2 73. 
   
 
 







Figure 5:  LC/UV (TOP) and LC/ Fluorescence detection of the peptide fragments produced by 
tryptic digestion of dynorphin A. Incubated for (A) 0, (B) 5 and (C) 30 min.72 






2.3.1.3 LC with radioimmunoassay (RIA) 
Quantitation of peptides and proteins by immunoassay methods is a highly specific method. 
The main principle of RIA assays is a competitive binding between a known amount of a radio-
labelled analyte and the unlabelled analyte in the biological sample to a highly specific antibody. 
This is followed by the separation of the antigen-antibody complex and unbound labeled fraction74. 
One method reported by Müller et.al.75 combines an LC separation method with 
radioimmunoassay (RIA) for an analytical method that can be used to determine the  three main 
metabolites of  Dyn A(1-13), (Dyn A(2-13), Dyn A(1-12), and Dyn A(2-12)) in blood samples. 
By combining a chromatographic method with RIA, the research group was able to detect very 
low concentrations of the neuropeptides. The LOD that was reached was 0.07 ng/mL for Dyn A(1-
13), Dyn A(2-13), Dyn A(1-12), and  0.21 ng/mL for Dyn A(2-12). This method was then used 
for the determination of the concentrations of Dyn A(1-13) and its metabolites in blood samples 
obtained from two human subjects that received I.V. infusion of either 250 µg or 1000 µg/kg of 
Dyn A(1-13) over 10 minutes. Compared to in vitro samples, the in vivo human blood samples 
showed a more rapid metabolism of Dyn A(1-13) and a shorter t1/2 than what was estimated from 
previously performed in vitro experiments by the same research group. This may be due to the 
involvement of blood vessels and other organs in the clearance of the neuropeptides. Although, 
RIA is a sensitive and selective method for the analysis of proteins and peptides in biological 
samples, there are some disadvantages of this approach. Among these are the difficulty in 
preparing the radiolabeled antigens and highly specific antibodies use for the RIA assay and the 




2.3.1.4 LC with mass spectrometry (MS): 
LC coupled to MS is one of the most reported methods used for the study of the activity 
and metabolism of Dyn A(1-17) and its metabolites, both in vivo and in vitro. Reed et.al 76 studied 
the metabolism of Dyn A(1-17) in the striatum of freely moving Fisher rats. Dyn A(1-17) was 
infused to the rats at a rate of 0.1µL/min for over 20 minutes, via a microdialysis probe, and the 
dialysate fractions were then collected at specific time points. Once the microdialysis samples were 
collected, they were analyzed by a MALDI time-of-flight analyzer and MALDI ion trap mass 
spectrometer for tandem mass experiments. In addition to MALDI, other mass spectrometry 
methods such as electrospray ionization (ESI) have been used for the study of Dyn.  
Beaudry et. al77 reported the use of LC coupled to a quadrupole ion trap mass spectrometer 
for the identification and quantification of three peptides that are involved in neuropathic pain 
(substance P, calcitonin gene-related peptide (CGRP) and Dyn A) in homogenized rat spinal cord 
samples. Our lab78 has previously performed LC-MS/MS using a triple quadrupole mass 
spectrometer to investigate the metabolism of Dyn A (1-17) by brain and spinal cord slices from 
Winster rats. Various fragments of Dyn A (1-17) were detected, including Dyn A (1-6), which is 
one of the major metabolites of the parent neuropeptide. In addition to this, our group has used 
LC-MS to investigate the transport of the peptide Dyn A(1-6) across a monolayer of bovine brain 












Figure 6: Side-by-Side® diffusion chamber used for monitoring in-vitro transport of Dyn A(1-6) 




2.3.2 Electrophoresis methods 
Dynorphin A(1-17) and most of its metabolites are charged peptides. This makes it possible 
to separate them by different electrophoretic methods such as capillary electrophoresis (CE). A 
limitation of the use CE in the determination of Dyn A and its metabolites is mainly due to 
electrostatic adsorption of the positvely charged peptides to the capillary walls. A more detailed 
explanation of the forces causing the adsorption and some of the strategies reported to decrease 
the undesirable peptide-wall interaction are described in chapter three.  
 
2.3.2.1 Capillary electrophoresis (CE) 
2.3.2.1.1 Capillary electrophoresis 
In vitro studies of the metabolism of Dyn A in human blood and rat brain tissue using CE 
was first reported by our lab 81. Dyn A(1-17) and four of its metabolites were separated by CE 
method that involved on-capillary complexation of copper (II) with nitrogens atoms of the peptide 
backbone [Figure 7]. Complexation of copper ion with peptides was found to improve UV 
detection and effect resolution of peptide separation. In addition, the complex exhibits selectivity 
for peptides in the presence of amino acids because a minimum of three amino acids residues is 
needed to form the complex. The copper-Dyn complexation was reported to increase both peak 
height and area of the Dyn A(1-17) and its fragments using UV detection. The adsorption of the 
basic peptides to the inner surface of the capillary wall was decreased by adding 25 mM phytic 
acid to the background electrolyte (BGE). The polyanionic molecules act as an ion pairing agent 
with positively charged amino acids residues, shielding them from the negatively charged silanol 



















2.3.2.1.2 Nonaqueous capillary electrophoresis 
Several benefits have been reported concerning the use of nonaqueous CE (NACE) 
compared to aqueous CE methods. These include the increased solubility of many nonpolar 
compounds in organic solvents82 and reduced aggregation of large nonpolar compounds83. This 
makes it possible for  NACE systems to separate analytes that have similar electrophoretic mobility 
in aqueous BGEs84. It also has better compatibility with a wide range of solvents to MS.  
The separation of the opioid peptides, Leu-ENK, and Met-ENK, was investigated by 
Psurek et al. 84 using NACE. The BGE consisted of 10 mM ammonium acetate in ACN/methanol 
(3:1). Capillaries utilized for the separation had an effective length (LD) of 60 cm and a total length 
(LT) of 67 cm with a 75 µm inner diameter (i.d.). The applied voltage was +25 kV. Detection was 
accomplished by both UV (215 nm) and electrochemical detection (60 µm Pt microdisk and a 
detection potential +0.65). Electrochemical detection showed a lower LODs (0.3 µM) by a factor 
of 10 compared to UV detection (~ 3.2 µM). 
  
2.3.2.2 Micellar electrokinetic chromatography (MEKC) 
Surfactants added to the BGE solution at concentrations above its critical micelle 
concentration (CMC) can form micelles. Micellar electrokinetic chromatography (MEKC) is a 
modification of capillary electrophoresis. MEKC separation is based on the partition of an analyte 
between the mobile phase (the bulk solution) and a pseudostainary phase (micelle) under an 
applied electrical field85-86. An attempt of the separation of a series of Dyn analogs by MEKC was 
reported by Fürtös-matel et.al 87 since the mixture could not be separated by RP-LC. The analogs 
shared 18 amino acid residues (FNXEDLRKQAKRYGGFLR) but differed only the position of 
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one residue (X=alanine) within their sequence. Three different surfactants were evaluated 
including sodium dodecyl sulfate (SDS) as an anionic surfactant, cetrimonium bromide (CTAB) 
as a cationic surfactant, and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate  
(CHAPS) as a zwitterionic surfactant. The capillaries used for the MEKC separation were 50 µm 
i.d. with a LD of 61.2 cm and LT of 69.7 cm. UV detection was performed at λs of 200 and 235 
nm.  Among the three surfactants used for MEKC separation of the 13 Dyn analogs, CHAPS 
showed the best separation.  The BGE used for the final MEKC separation consisted of 100 mM 
sodium phosphate (pH 3.5) and 35 mM CHAPS with an applied field strength of +360 V/cm. The 
addition of  CHAPS within the BGE improved the separation compared to the addition of CTAB, 
due to the differences in the way the two surfactants form aggregates within the BGE solution, and 
CHAPS showed a much lower affinity to the Dyn analogs. 
   
2.4 Summary 
The chapter gives a general overview opioid peptides, and their receptors, with a more 
detailed look at dynorphins distribution within CNS, its metabolism, in addition to, the 
pharmacological and pathophysiological effects of elevated levels of the neuropeptides due to 
different diseases states such as spinal injury. 
The chapter also covered different analytical methods used for the investigation of Dyn’s 
metabolism and pathophysiological effect caused by up normal levels of the peptide within animal 
models. The most widely reported method utilized for the investigation of Dyn A and metabolites 
has been chromatographic methods. Although LC methods are the most widely used techniques, 
they can require large volumes of sample and mobile phase. Reported articles that use CE 
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techniques for the analysis of Dyn are limited. The fact that CE requires small (submicroliter) 
sample volumes, and provides high separation efficiencies, as well as the ability to couple CE with 
microdialysis sampling (including the microfluidic platform), makes it an attractive separation 
technique for neuropeptides.   
Mass spectrometry and UV detection are the most widely used detection methods paired 
with LC and CE for the detection of dynorphins. Other sensitivity and selectivity detection 
methods have been used such as fluorescence detection. This chapter briefly covered some of the 
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Capillary Electrophoresis and Electrochromatography Methods for the 




3.1.1 Capillary electrophoresis 
Capillary electrophoresis (CE) is a separation method that is based on the migration of 
charged species in a background electrolyte solution (BGE) within a narrow capillary under the 
influence of an applied electric field [Figure 1].  
Some of the advantages of CE over other separation techniques, such as liquid 
chromatography (LC) includes higher separation efficiencies. This is due to the flat plug flow 
profile of CE in contrast to the parabolic profile of pressure driven flow systems. CE also requires 
low sample volumes (pL to nL vs. µL), small amounts of BGE (< 20 µL), short analysis times, 
and has a low cost of operation and instrument maintenance. As the separated analytes move 
through the capillary, various detection methods can be used such as ultraviolet (UV), laser 
induced fluorescence (LIF), mass spectrometry (MS), amperometric and conductivity detection. 
 
3.1.1.1 Theory of CE 
The velocity (v) at which an ion travels within the capillary can be expressed as: 
        v = µeE                     (1) 
where (E) is the electric field strength and (µe) is the ion’s electrophoretic mobility. The 
electrophoretic mobility of an ion is proportional to the charge of the ion (q) and inversely 
proportional to the ions radius (r) and the viscosity of the BGE.  
                    µe= 
𝑞
6𝜋η𝑟⁄                   (2) 
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Equation (2) shows that highly charged small ions have higher electrophoretic mobilities, 
compared to larger ions of the same charge. Another important feature of CE is that under the 
influence of applied electric field, there is a bulk flow of the BGE within the capillary due to 
electroosmosis, termed electroosmotic flow (EOF) [Figure 2]. When a capillary is filled with an 
electrolyte solution, positivity charged ions of the buffer are attracted to the negatively charged 
silanol groups of a fused-silica capillary, creating an electrical double layer and a potential 
difference at the capillary wall (zeta potential (ξ)). 
µeo = (εoεrξ)/η       (3) 
             ξ = (σδ)/(εoε)      (4) 
where µeo is the EOF mobility, (εo) is permittivity of a vacuum, (εr) is relative permittivity of 
medium (dielectric constant) and where δ is the thickness of the electrical double layer. The EOF 
is dependent on a number of factors that includes pH and the ionic strength of the BGE. From 
equation (3) we can see that µeo is proportional to the zeta potential at the surface. 
The overall migration time of an ion under an applied electrical field is related to both the µe and 
µeo : 
                       vapp = (µe + µeo) E = (µe + µeo) (𝑉 𝐿⁄ )           (5) 
where (vapp) is the apparent velocity, and E is a function of the applied voltage (V) and (L) is the 
length of the capillary. From equation (5) we find that small highly charged cations show the fastest 
velocity, followed by larger size cations of the same charge, then all the neutral molecules migrate 
togther in a single zone, and then large anions follow and then finally small highly charged anions 
[Figuer 2].  
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Although CE has been shown to provide high-efficiency separations of many analytes, 
unfortunately there are some sources of band broadening found in CE. They include Joule  heating 
due to the resistance of the BGE to the flow of current that leads to an insufficient dispersion of 
heat across the capillary 1-2. Joule heating can be minimized by using narrow inner diameter (i.d.) 
capillaries, which dissipate heat more effectively. However, smaller i.d. capillaries also shorten 
the optical path length and increase the limits of detection for CE-UV compared to LC-UV. Other 
sources of band broadening in CE includes the nonspecific adsorption of analytes onto the inner 
walls of capillaries, which may require additives to the BGE or modification of the capillary wall.     
 
 





Figure 2: Schematic of the separation mechanism for capillary and microchip electrophoresis. 
 
3.1.2 Microchip electrophoresis 
Microchip electrophoresis (ME) is a miniaturized version of CE and operates under the 
same separation mechanism. ME is a separation system that has the potential to assay multiple 
samples within minutes3 (high throughput). The microchip design can include sample preparation, 
derivatization, injection, separation, and detection all in a single microfluidic platform4. ME has 
minimal sample requirements (as low as picoliters) and uses short separation channels along with 
high field strengths to produce rapid separations5. This makes microchip electrophoresis an 
attractive method for high throughput analysis of protein/ peptide samples. 
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Microchannels in ME are most commonly fabricated either by photolithographic or 
micromolding methods. To perform a separation by ME, the BGE and sample are loaded onto the 
chip, and the sample is introduced into the separation channel electrokinetically through the 
application of a high voltage at the sample and buffer reservoirs. The analytes can then be detected 
by laser induced fluorescence (LIF)6-9, electrochemistry10, conductivity11, or mass 
spectrometry(MS)12-13. 
 
3.1.2.1 Microfabrication methods and materials 
Microchannels in ME typically have a channel width of less than 200 µm and depth of less 
than 50 µm. The most commonly used material for fabrication of ME devices is glass (soda lime, 
borofloat, or high-quality quartz)14-15. Glass substrates are not only known for their excellent 
optical properties16 but also their well-understood surface chemistry, compatibility with most 
solvents and well-developed fabrication procedures. Other materials that are commonly used in 
ME are polymers such as polymethylmethacrylate (PMMA), polydimethylsiloxane (PDMS), 
polyvinyl chloride (PVC)17, polyimide (PI), and cyclic olefin copolymer18-19. The advantages of 
using polymers for ME are the simplicity of fabrication and low cost of the produced microchips. 
This makes it possible to produce disposable MC devices15, 20. Table 1 shows some of the 
properties of glass and various polymers used in ME. 








 Glass  PDMS PMMA PI 
Useful temperature range (ºC) < 500 −40 to 50 −70 to 100 −73 to 240 
Thermal conductivity (W/mK) 1.2 0.17 to 0.3 0.186 0.2 
Visible transmittance (%) > 90 91 92 87 
Surface charge (native) Yes Weak Yes No 
Acid resistance  Excellent Fair-good Good Fair-good 
Base resistance  Excellent Poor-fair Excellent Fair-good 
Solvent resistance Excellent Poor Poor Fair 
  
Table 1: Comparison of glass and various polymers used ME. PMMA: polymethylmethacrylate, 
PDMS: polydimethylsiloxane, and PI: polyimide. [Table from L.A. Legendre, et.al.]21  
 
3.1.2.1.1 Glass chip fabrication procedures 
Standard photolithography followed by wet etching is the most commonly used method for 
glass chip fabrication 22. This technique requires a glass substrate coated with two layers; the first 
is a chromium layer that functions as a sacrificial etching mask. The second is a photoresist layer 
that functions to provide the chip design and helps protects the substrate from chemical etching. 
The photoresist is placed over the glass-chromium substrate by spin coating. The photoresist most 
commonly used is a positive photoresist (soluble in the developer after light exposure) although, a 
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negative photoresist can also be used (insoluble in the developer after light exposure). The choice 
of which photoresist is used for fabrication will depend on the design of an opaque film with a 
defined transparent pattern (photomask) that is placed over the photoresist.  
The photoresist coated substrate is then exposed to UV light through a microchip design 
pattern that is defined by a photomask. The UV exposure time mostly depends on the power of the 
UV source and the thickness and type of photoresist. The UV exposed photoresist is then removed 
using a developer solution (containing approximately 2% tetramethylammonium hydroxide in an 
aqueous solution). The Cr layer is then removed by a Cr etchant solution consisting of a mixture 
of perchloric acid (HClO4), and ceric ammoniumnitrate (NH4)2[Ce(NO3)6] to reveal the underlying 
glass. The exposed glass is then etched using a concentrated HF/HNO3 solution. The rate of etching 
depends on the type of glass being etched and the concentration of HF used. The etching rate is 
controlled by maintaining a constant temperature 23. Once the desired channel depth is reached, 
the acidic etching solution is neutralized by washing the chip with a CaCO3
 suspension, and the 
remaining photoresist and Cr are removed by immersing the glass substrate first with acetone 
followed by Cr etchant solution. Access holes are then drilled to generate reservoirs at the end of 
each of microfluidic channels, and finally, the substrate is bonded to a coverplate [Figure 3].  
The most frequently used bonding procedure is thermal bonding. In this case, two glass 
plates are brought to close contact by applying vertical pressure to the surface and then subjected 
to a high temperature (550-650 °C) for several hours. It should be noted that both glass surfaces 
must be extremely clean to avoid dust particles affecting the glass bonding and this required 
condition is found in a cleanroom environment 24-25. Other, less frequently, used methods for chip 
bonding include chemically activation.  In this case, a small volume of 1% HF solution is placed 
between the two glass substrates and kept at room temperature while applying perpendicular 
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pressure over the glass chip using weights for 24 hours26. Anodic bonding is another method that 
can be used for bonding of a glass/glass or glass/silicon microchips. With anodic bonding the two 
substrates are clamped together under temperatures of approximately 400°C and placed between 
two metal electrodes and an external voltage of 1 kV is applied. An irreversible chemical bond 
between the two substrates occurs. The bonding is due to the migration of the Na+ ions of one 
substrate to the negative electrode, producing a strong electrostatic attraction to the second 
substrate layer 27-28. Other methods include adhesive bonding, where glue guide channels are 
fabricated along the microchip channels and reservoirs of the glass substrate. The glue guide 
channels then are filled with UV-curable glue, and the glass coverplate is then placed over the 
etched plate.  Finally, the chip exposure to a UV light for 30 min, bonding the two glass substrates 





Figure 3: General scheme showing glass microchip fabrication steps 
  
3.1.2.1.2 Polymer material fabrication procedure 
3.1.2.1.2.1 ME fabrication by laser ablation  
The approaches used for the fabrication of polymer microchips are mostly controlled by 
the nature of the polymer materials used. One method involves the breakdown of covalent bonds 
of long chain polymer materials using a short wavelength laser to form the ME channels. The 
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position of the laser is controlled by an X-Y stage.  Some of the materials used to make ME devices 
with this method include polycarbonate, PMMA 30, and PDMS 31. A method was described by 
Fogarty et.al. 31 using a CO2 laser for the ablation of microchannel within a PDMS substrate. A 
standard hole puncher was then used to make the reservoir holes at the ends of the ablated channels. 
This procedure had the advantages of being rapid and relatively inexpensive. The ME chips 
produced using this approach were used for the separation and detection of fluorescent 
cyano[f]benzoisoindole (CBI) derivatized neurotransmitters (glutamate and aspartate) by LIF 
detection. 
 
 3.1.2.1.2.2 Injection molding and casting fabrication procedures for polymer microchips  
Both injection molding and casting microchannel fabrication share two initial steps, the 
first step is the fabrication of a mold or a master. The second step is the transfer of the channel 
design of the mold onto the polymer material or substrate. Injection molding is a high-throughput 
production method for the fabrication of microfluidic devices and has a low production cost. In 
this approach, acrylic substrates are initially melted and then injected into a reusable master 32. 
The casting method is an alternative and more simple and popular method used for ME 
fabrication. Polymer materials, for example, PDMS, are mixed with a curing agent and poured 
onto a master e.g. silicon master. The polymer is then cured at room temperature. The 
polymerization reaction can also be accelerated at higher temperatures 33-34 [Figure 4]. The surface 
chemistry of the PDMS polymer can be controlled by changing the monomer-curing agent ratio. 
Once the PDMS polymer is cured, the PDMS is peeled off from the master, and reservoir access 
holes are made at each end of the microfluidic chip using a standard hole puncher or biopsy 
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punches. The final step involves the bonding of the PDMS substrate containing the channels to a 
cover layer (e.g. glass or PDMS). The bonding strength of the two layers may be a weak bond 
(Van der Waals forces), that allows a reversible seal of the chip, or a stronger irreversible seal can 
be produced by exposing both surfaces to an oxygen plasma. 
 
 





3.1.2.2 Microchip design and sample injection   
Various microchip designs have been used for ME, from a simple channel to a complex 
design with multiple channels within the microfluidic chip. The sample can be introduced into the 
ME separation channel by several different methods. They are based on the ME chip design and 
injection requirements. For ME devices with a simple t-design, the three most popular methods 
are floated, pinched and gated injections. 
Floating injection [Figure 5A] can be performed by using a single power supply 35. The 
sample is injected electrokinetically by applying a high voltage (HV) to the sample (S), with the 
buffer waste (BW) reservoirs, and the sample waste (SW) reservoirs  kept at ground, and the buffer 
(B) reservoir left floating for 1-5 seconds. This causes the sample to be introduced into the 
separation channel. In the dispensing step, a HV is applied to the (B) with the (BW) kept at ground 
and the (S) and (SW) floating. A disadvantage of the floating injection method is the 
irreproducibility of the injection volumes and a large sample plug that is due to the absence of 
pushback flow from the (S) and (SW) 36-37. 
  
Pinched injections [Figure 5B] require power supplies that are connected to each of the 
four reservoirs. A sample is loaded by applying a HV to the (S), (B) and (BW) with the (SW) kept 
at ground for a given moment. Once the tee is filled with the sample, the sample plug is injected 
into the separation channel by applying a HV to (B), and at the same time, a fraction of the HV is 




The third injection method used in ME is the gated injection method. This injection method 
requires a minimum of two power supplies. Unlike the first two methods, the sample is first placed 
in the top reservoir and the BGE is placed in one of the side channel reservoirs of the ME [Figure 
5C]. In the loading step, a high voltage is applied to the (B), and a fraction of the high voltage is 
applied to the (S). With both the (SW) and (BW) kept at ground causing a gated to form. The 
sample is then introduced into the separation channel by floating the (B) voltage (less than 5 
seconds), and a plug is formed within the separation channel. This is followed by restoring the 
applied voltages causing the sample plug to flow to the (BW). The amount of voltage applied to 
both (B) and (S) are determined based on the field strength required for the separation. This is 
calculated based on the junction voltage at the ME intersection and calculated using Kirchoff’s 
Laws.  The gated injection method can be utilized for continuous sampling but suffers from 








Figure 5: Sample injection methods in electrophoresis microchip. A) Floating injection, B) 
Pinched injection, C) Gated injection. S: sample, B: buffer, SW: sample waste, BW:  







3.2 Limitations of CE and ME for protein/ peptide analysis 
Protein and peptide analysis by CE or ME can be limited by irreversible adsorption of these 
substances onto the inner walls of the fused silica capillaries or glass substrates normally used for 
separations. This is especially a problem with basic proteins and peptides [Figure 6]. Protonation 
of the amino group at the N-terminal or basic amino acid residues, such as arginine and lysine of 
a protein/peptide, may affect the CE separation of a protein/peptide due to electrostatic interactions 
with the silanol surface.  Analyte adsorption can lead to peak tailing, poor efficiency, loss of 
analyte, lack of reproducibility of migration time39 or instability of baseline. Therefore CE or ME 
may not always be the best option for protein/ peptide analysis 40.  
Proteins are high molecular weight molecules, composed of simple amino acids linked 
together by peptide bonds, forming long polypeptide chains that are known as the primary 
structure. Several polypeptide chains, each with its specific sequence of amino acid residues, can 
form secondary structures (α-helix or β-sheets) through H-bonding. Also, the polypeptides chains 
can fold to form more complicated and unique tertiary structures through hydrogen bonding, polar 
interactions, nonpolar interactions, disulfide bonds and/or salt bridges. Finally, a more complex 
protein structure can also occur through intermolecular interactions between two or more tertiary 
structures causing the formation of the protein quaternary structure. Also, many proteins may also 
contain other components such as saccharides, lipids or metals. The complexity of a proteins 
structures can lead to a protein having several different surface chemistries. The same protein can 
possess nonpolar, polar, cationic and anionic properties on different parts of the protein surface. 
In addition, the properties of a protein can be sensitive to changes in the overall environment in 
which the proteins are placed, such as pH, ionic strength, temperature or solvent composition. It 
should be noted that not every interaction of the protein with the surface (e.g. inner surface of a 
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fused silica capillary) will result in adsorption. It will occur only when the protein is in the correct 




Figure 6: Image of fluorescence labeled protein adsorption onto fused silica capillary. FITC-anti-
human-β2gpI in pretreated capillaries with (A) BGE (50 mM phosphate buffer pH 7.4), 
(B) HCl, and (C) NaOH. Note: FITC‐anti‐human‐β2gpI was incubated for one hour at 






protein may not always be electrostatically repelled by the negatively charged silanol groups of a 
capillary wall.  A possible explanation may be that, although the overall charge of the protein is 
negative, positive patches of the protein in a specific orientation can be electrostatically adsorbed 
onto the negatively charged capillary wall and result in protein adsorption 44. 
One model used to explain adsorption of proteins/ peptides onto the surface of a fused silica 
capillary is shown in figure 7 45. The first step involves the transfer of the protein/ peptide to the 
surface. The second step is the interaction and adsorption of the protein/ peptide at the surface. 
From the model, it shows that based on the protein/ peptide, medium, and the residence time of 
these molecules on the surface, the adsorption in some cases may be reversible 46. Graf et. al. 47 
investigated the strength of the protein adsorption to fused silica capillaries in CE as a function of 
pH and buffer constituents. Model proteins were used in the study, which included cytochrome c 
(pI 9.6) as a basic protein, myoglobin (pI 6.8-7.4) as a neutral reference and β-lactoglobulin (pI 
5.4) as an acidic protein. The research group studied the protein adsorption to the capillary due to 
different CE conditions and their effect on the reproducibility of the EOF. One major parameter 
that was investigated was the pH dependence of protein adsorption. They found that myoglobin 
showed strong adsorption at pH values below its pI, and a negligible adsorption at pHs near or 
above its pI. The two proteins, cytochrome c and β-lactoglobulin, were reported to show less 
protein adsorption to the capillary at pHs above their pIs. The group also investigated the 
regeneration of the myoglobin adsorped onto the capillary by rinsing the capillary with sodium 
dodecyl sulfate (SDS) within the BGE after subsequent runs of a protein sample. Capillary 
regeneration was possible only when recently adsorbed myoglobin was rinsed with SDS. This was  
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accomplished by simply rinsing the capillary with buffers containing 200 mM SDS for 3 hours. 
Unfortunately, capillary regeneration with SDS was not successful for longer contact times (after 




Figure 7: Protein adsorption model (with adaptation). 45 
   
3.3. Strategies for the separation of basic protein/ peptides by CE 
Some of the strategies that haven been reported to improve efficiency and resolution of 
protein/ peptide CE separation include an adjustment in BGE strength, pH, or the addition of 




3.3.1 Adjustment of the ionic strength of BGE 
Two methods used to enhance the separation efficiency of protein/ peptide CE separations 
are through the use of sample stacking and high ionic strength BGE 50. Sample stacking is an on-
column concentration technique that requires that the sample to have a lower conductivity than of 
the BGE. When a voltage is applied within the capillary, the differences in concentration of 
electrolytes (conductivity) between the sample plug and BGE, cause ions in the sample to 
experiences a higher electrical field then the rest of the capillary. Therefore, ions stack at the 
boundary between the sample region (high electrical field) and the BGE region (lower electrical 
field).  
For example with cations, the high electrical field strength in the sample region causes 
positively charged analytes to migrate fast until they reach a low field strength of the BGE where 
they slow down and stack at the sample BGE region interface [Figure 8] 51. This sample stacking 
techniques may provide higher peak efficiency and sensitivity enhancement in CE and can be 
beneficial for high sensitivity analysis of proteins/ peptides. One CE-MS investigation of the effect 
of sample stacking was performed by Yang et.al52 on synthetic and bioactive peptides. They 
investigated the impact of the sample soloution properties such as acidity and conductivity on 
sample stacking. They reported better detection limits with a 3000-fold enhancement of sensitivity, 
with peptide detection of concentrations in low nano-molar range. 
 The use of a high ionic strength BGE can also reduce analyte adsorption by suppressing 
the ionic interactions between charged proteins/peptides and the ionized silanol groups of the 
capillary wall. However, some caution must be taken since high ionic strength BGEs can cause 
hydrolysis or denaturation of some proteins 50. Also, a high concentration BGE within the CE 
system will alter the double layer thickness, leading to a decrease in the EOF and an increase the 
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migration times of analytes. Also, BGEs with very high ionic strengths may lead to Joule  heating, 
thus requiring lowering the current by applying a lower voltage across the capillary. 
  
3.3.2 Adjustment of BGE to basic pH 
CE analysis of proteins and peptides at extremes of pH has been used to minimize analyte-
wall adsorption in particular cases, but not as a general strategy for protein/peptide separations 
[44]. The adjustment of the pH of BGE to alkaline pHs will provide a faster EOF through 
increasing of the ionization of silanol groups at the surface of fused silica capillaries [Figure 9]. 
Most proteins/ peptides are zwitterionic molecules. Therefore, at basic pHs (pH 8-11), there is a 
reduction of the protonation of the N-terminus, and amino group residues, such as in lysine, and 
an increase in the ionization of the C-terminus and acidic residues of these molecules. For proteins 
or peptides with pI < pH of the BGE, alkaline conditions cause an increase in the number of ionized 
silanol groups on the surface of fused silica capillaries as well as increase the overall negative 
charge of the protein or peptide. This may cause an electrostatic repulsion to occur and lead to a 
decrease in protein/ peptide adsorption on the capillary surface49, although the negatively charged 
species will favor to migrate to the anode, the stronger EOF drives the charged species to the  
cathode. This phenomenon has been reported by Lauer and McManigill 53 in the separation of 
several proteins with pIs ranging between 7 and 11.  
It should be noted that, in some cases, an extreme increase in the pH of the BGE can result 
in damage or hydrolysis of the protein or peptide 54. In addition, precipitation may occur when the 
pH of the BGE is approximately equal to the pI of the protein/peptide. The loss of protein/ peptide 
by precipitation may be minimized by the addition of a surfactant or organic solvents within the 
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BGE. It is advised not to run CE analyses at pHs above pH 11. This is because Joule heating is 
observed at these pHs due to high currents produced by BGE with pH >11. In addition dissolution 
of the silica can slowly start and causes change in the EOF over time 54.  
 
 





Figure 9: The effect of pH on EOF mobility for a fused silica capillary.55 (Reprinted with 
permission) 
   
3.3.3 Adjustment of BGE to acidic pH 
A less popular approach to enhance protein/ peptide separation is by the adjustment of the 
BGE pHs to an acidic pH (2.5-5.0) 52, 54. Lower pHs cause a lower number of ionized silanol groups 
on the capillary surface. This reduction of the number of activated silanol groups can enhance the 
separation efficiency by minimizing electrostatic attraction of positively charged protein/ peptide 
with the capillary wall, in addition to suppressing the EOF 56. In addition; operating at pHs below 
the protein/peptide pIs will cause protonation of protein/ peptide and yield faster mobility of the 
analyte to the cathode and may affect the resolution of the separation.  
McCormick 57 published one of the first papers on CE separations of protein mixtures using 
low pH phosphate buffers (pH 1.5 to 5.25).  He found that at very low pH values, poor separations 
occurred due to the similarity of mobility of the proteins in the mixtures to be separated at pH 1.5.  
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However, when the proteins mixture was analyzed at a higher pH (4.0), the mobility differences 
between the proteins became larger and enhanced their separation. Further increases in BGE pH 
above 5.2 lead to worsening of both resolution and separation efficiency due to the increased EOF 
and peak tailing due to adsorption of the proteins.   
  
3.3.4 Addition of background electrolyte additives  
Dynamic coating of the inner wall of the capillary by physical adsorption of the coating 
material dissolved in the BGE, can reduce the undesirable adsorption of analytes and/or may 
reduce the EOF. The dynamic coating method is an attractive approach due to the simple and quick 
coating process.  In addition, it is easy to remove of the coating material from the capillary walls 
using appropriate rinsing procedure. Surfactants are the most widely used BGE additives for 
dynamic coating. These include both ionic and nonionic surfactants. Other additives can also be 
used such as amines, short chain polymers and ionic liquids (IL) 58-59.  
Cationic surfactants, such as dodecyltrimethylammonium bromide (DTAB), 
cetyltrimethylammonium bromide (CTAB) and didodecyldimethylammonium bromide (DDAB) 
60-62, are frequently added to the BGE to reduces electrostatic adsorption of positively charged 
protein/ peptides with negativity charged silanol capillary walls and cause a reversal of the EOF 
due to the adsorbed cationic surfactants onto the inner capillary wall. Although, DTAB and CTAB 
are the most widely used cationic surfactants used for dynamic coating in protein /peptide CE 
separations, newer materials have been frequently tested. For example, the novel positively 
charged surfactant, N-dodecyl-N,N-dimethyl-(1,2-propandiol) ammonium chloride (DDPAC), 
was synthesized by Znaleziona et.al. 58 and used as a dynamic coating in CE. The cationic 
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surfactant caused reversal of the EOF and reduction of the electrostatic adsorption. It was then 
possible to separate a mixture of basic proteins that included ribonuclease A, myoglobin, lysozyme 
and cytochrome c. The best separation was achieved by using a BGE of 100 mM acetate (pH5) 
containing 10.0 mM DDPAC. The separation was then compared to one obtained using equal 
concentrations of DTAB or CTAB in 100 mM acetate (pH5). Separations using DDPAC as the 
BGE additive provided better resolution of the four proteins as well as separation efficiency 
compared with DTAB or CTAB. 
The reported applications of ionic liquids (IL) to CE peptide/protein separations are 
limited.  An example of the use of ionic liquids as a stationary phase using the dynamic coating 
method was described in the research article by Guo et.al 63. N-methyl-2-pyrrolidonium methyl 
sulfonate was used as an additive within the BGE and increased the CE separation efficiency of 
several basic proteins such as lysozyme, cytochrome c, ribonuclease A, and α-chymotrypsinogen 
A. Under optimal separation conditions (pH 5), the protonated amine of the IL is electrostatically 
attracted to the negatively charged silanol groups of the capillary wall in addition to the formation 
of a hydrogen bond between the N−H of amine and the silanol groups of the capillary [Figure 10]. 
A fast baseline separation of the four proteins was obtained with the coated capillary (i.d. = 75 µm, 
LT = 50 cm, LD = 41cm), with the separation efficiency ranging from 209,000−448,000 plates/ m.  
 
3.3.5 Capillary gel electrophoresis 
The most popular and most widely used form of electrophoresis for the separation of 
proteins is sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), where 
proteins are separated by differences in size of the produced SDS-proteins complex. This technique 
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is known to be a time consuming and labor intensive method that requires multiple steps 
(preparation of the gel, sample preparation, loading, and staining). Capillary gel electrophoresis 
(CGE) is the capillary version of slab gel electrophoresis. CGE  has the advantage of having a high 
resolving power, on-column detection and protein quantification64.  
The major difference between CGE and CE is that with CGE the separation medium is a 
sieving matrix, whereas in CE the separation medium is the BGE. Different sieving matrixes have 
been used in CGE; these include linear and cross-linked polyacrylamide, polyethylene glycol, and 
dextran65-66. Mostly within CGE, proteins are treated with a detergent (most commonly SDS) 
causing the charge differences between proteins to be normalized (i.e. having the same charge-to- 
mass ratio, however this assumption may not always hold for positively charged and hydrophobic 
proteins). The EOF in CGE is mostly suppressed, and the separation of proteins are mainly based 
on the mobility of a SDS coated protein within the sieving matrix, with smaller size proteins having 
the greatest mobility. Differences between SDS-CGE and SDS-PAGE, include the ability to be 
automated with on-line detection and the fact that protein quantification can be accomplished in a 
shorter time, since higher field strengths can be applied. 
The capillary format is the most common format for gel electrophoresis in both 
pharmaceutical and biological research laboratories, next to slab-gels. Microchip devices have also 
been used for gel electrophoresis of proteins 67. A major advantage of performing capillary gel 
electrophoresis (MCGE) in microchannels is the fast separation time of microchips compared to 
capillaries. P. Schultz’s (1999) 68 lab was one of the earliest research groups to transfer SDS-CGE 
based methods from capillaries to the microchip format, reporting the separation of a mixture of 
six proteins with a molecular weight ranging from 9 kDa to 116 kDa in less then 40 seconds. More 
recently Seyfried et. al. 69  reported the successful separation of PEGylated human serum albumin 
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(PEG-HSA). This method was used to determine the degree of PEGylation in a reaction sample of 
HSA with a 20 kDa branched PEG [Figure 11]. Compared to SDS-PAGE, Seyfried was able to 
combine the time consuming multi-step process of the conventional SDS-PAGE method into a 
one-step MCGE system.  






Figure 10: (A) The structure of [NMP]+CH3SO3
− (B) the interaction between [NMP]+CH3SO3
− 
and the silica capillary wall; (C) the mechanism of separation of proteins using 
[NMP]+CH3SO3











Figure 11: MCGE electropherogram of separation of a multiply PEGylated protein HSA sample.69 




3.4 Capillary electrochromatography 
Capillary electrochromatography (CEC) is a technique that combines the principles of 
capillary electrophoresis (electroosmotic flow of bulk solution and electrophoretic mobility of the 
analyte) and principles of chromatography (distribution of the analyte between the stationary and 
mobile phases).  The technique was first reported by Strain (1939) for the separation of a mixture 
of dyes using an applied electric field across a packed column70. According to F. Svec and other 
authors, the term electrochromatography was coined by Berraz in 194371-73. Decades later, CEC 
has grown in popularity with applications in a broad number of areas including environmental, 
food and pharmaceutical analysis74-75 in addition to, proteomic research76, disease biomarkers, or 
pharmaceutical and biotechnology products77. Proteins/peptides differ from each other in charge, 
polarity, molecular mass and solubility among many other physical or chemical properties. As 
described above, CE separations of peptides and proteins are primarily based on the differences of 
the charge to hydrodynamic size. However, in CEC other parameters may influence the separation. 
The main one being differences in polarity causing adsorption/partitioning events to occur at the 
surface of the stationary phase. Other separation parameters that may influence resolution include 
pH and the type and fraction of nonaqueous solvents within the CEC BGE (mobile phase).  
 
3.4.1 Theory of CEC 
The most frequently used classifications systems for CEC analysis of protein/ peptide are 
based on the capillary column format and the mode of separation. The first can be divided into 
packed partials columns, monolithic columns, and open-tubular capillary electrochromatography 
(OT−CEC) [Figure 12]. The mode of separation is based on differences in the stationary phase. 
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Examples include normal phase (NP), reverse-phase (RP), cationic or anionic ion-exchange, 




Figure 12: Classification of the packing state for columns for capillary electrochromatography: 
(A) packed stationary phase CEC column, (B) monolithic CEC column, (C) open-
tubular CEC column. 
 
Unlike LC, flow in CEC is generated by EOF, rather than pressure, because both the surface 
of the capillary wall and the stationary phase are charged. A plug-like flow profile is therefore 
produced inside the capillary78. Similar to CE, the magnitude of the EOF in CEC is proportional 
to the zeta potential of the electrical double layer at the surface of the stationary phase78. 
µeo = (εoεrξ)/η     (3) 
where (εo) is permittivity of a vacuum, (εr) is relative permittivity of medium (dielectric constant) 
and (η) is viscosity of the solvent.  
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In packed CEC, the surface area of the stationary phase is significantly larger than of the 
surface wall, and subsequently the contribution of the wall to the EOF is small, and the zeta 
potential is affected by the charge density at the surface (σ)78. 
ξ = (σδ)/(εoεr)     (4) 
The liner velocity of the fluid in a EOF driven CEC system is proportional to the electrical field 
strength. 
ueo = µeoE = (µeoV)/L     (6) 
From equation 6, it can be seen that higher field strengths cause an increase of the EOF. For a 
packed CEC column, the porosity of the packaging is considered to determine the mobility of the 
mobile phase. Also the CEC flow is affected by the physical characteristics of the mobile phase (ε 
and η), its ionic strength, the surface charge (due to the pH and the stationary phase properties). 
For a monovalent electrolyte, the thickness of the electrical double layer (δ) is affected by 
molar concentration (c) of the electrolyte79: 
δ = [(εoεrRT)/(2cF
2)]0.5            (7)  
where T is absolute temperature, R is the universal gas constant (8.314 J/ mol. K) and F is Faraday 
constant (9.65 × 10 4 C/mol.). From equation 7, we can see that the higher concentration of the 
BGE will decrease thickness of the double layer and that will lead to a decrease in the EOF.  
CEC has the potential to provide high-efficiency separations of proteins/peptides since the 
flow in CEC is a plug like leading to less dispersion. The Van Deemter equation can be used to 
illustrate the effect of different factors on band broadening:  
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H = A + B/u + Cu            (8) 
h = H/dp            (9) 
Where (H) is the plate height, (u) is the average linear velocity, h is reduced plate height, and dp is 
the CEC particle size. The term A, B, and C are eddy diffusion, longitudinal diffusion, and mass 
transfer terms respectively. The A, B, and C terms can be quantified, and equation (8) can be 
presented as78:  
H = 2λdp + 2γDm + c(dp
2/Dm)       (10) 
 
Where (λ) is packing factor, (γ) is the stationary phase obstruction factor, (Dm) is the analyte 
diffusion coefficient. Unlike LC, in CEC the effect the A term is minimal, because of the plug flow 
profile of the EOF this lowers the multipath band dispersion 80. Moreover, the C term is also 
reduced compared to LC due to intra-particle EOF through the porous particles that have a lower 
mass transfer resistance. The lower values of the A and C terms in equation (8) for CEC, explains 
the high efficiency obtained with CEC separation compared to LC. Also, due to plug flow of the 
EOF, the flow velocity is independent of particle size in CEC, and longer capillary columns with 
small particles can be used without worrying about back pressure81. 
 
3.4.2 Packed columns 
CEC based packed columns were used in the earliest applications of CEC 82. Typically, 
fused silica capillaries are used that have inner diameters of less than 100 µm with particle sizes 
between 1.5-5 µm80. The packing materials used for CEC are the same particles that are commonly 
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used for reverse phase or ion exchange liquid chromatography (LC). For example, most of the 
research that has been done concerning RP-CEC used C18-modifed silica particles (1.5-5 µm in 
diameter). Table 2 lists commonly used packing materials for RP-CEC 80. The packing methods 
that are used for packing CEC columns are similar to those employed for LC columns. These 
methods include pressure packing of slurries of particles in LC solvents, supercritical CO2, 
electrokinetic packing, using centripetal forces, or gravity83-84. A more detailed description of each 
of these methods can be found in the review by Colon et. al. 2000 83.  
   
Packing material  Particle size (µm) 
Hypersil C18 3, 5 
Spherisorb C18 3 
Nucleosil C18 3, 5 
Zorbax C18 6, 7 
Gromsil C18 3,5, 7 
Vydax C18 3, 5 
 
Table 2: Commercially available reversed phase packing materials commonly used in CEC. 
[Table from Li.et.al. 80] 
 
3.4.2.1 Reversed phase CEC 
The first separation of peptides using reversed phase CEC was reported by Schmeer et. al. 
1995 88-89. They separated a mixture of enkephalin methylester and enkephalin amide, using a CEC 
column packed with 1.5 µm RP stationary phase coupled to mass spectrometry. More recently, a 
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number of other application for the analysis of protein/peptide have been reported, due to the 
advances in packing technology of CEC columns 88. 
Liu et al. reported a rapid preparation method for capillary CEC columns. This method 
involves the use of the CEC mobile phase solution as the packing and conditioning solvent and 
allows for rapid preparation of capillary columns based on a single particle fritting technology. 
This led to a high throughput preparation of CEC columns (1 column/h) that included all the 
fritting, packing and conditioning steps, compared with a time-consuming multistep CEC column 
fabrication process − e.g. sinter-fritted columns − that may take up to a total of 12−24 hours to 
complete. These RP CEC columns showed a high efficiency (150,000 N/m) and a retention times 
reproducibility of less than 0.8% RSD with a standard peptides mixture (Gly-Tyr, Val-Tyr-Val, 
Met-enkephalin, Leu-enkephalin and angiotensin II) 90.  
Other research groups have studied the separation performance of different packing 
materials within the CEC columns on the separation of a cytochrome c tryptic digest. The peptides 
were separated on C18 silica-based stationary phases of different properties and origin, in addition 
to a CEC capillary packed with cyanosilca particles. It was reported that both C18 and cyanosilca 
CEC columns obtained high separation efficiencies, in addition to short analysis times. Their work 
also showed that the cyanosilca particles CEC packed capillaries provided an overall better 
separation of a cytochrome c tryptic digest 91. 
It should be noted that individual amino acids, charge, size, hydrophobicity, and sequence 
can impact the overall charge density and hydrophobicity of proteins/ peptides and affect their 
CEC elution behavior. One study investigated the effect of C18 CEC retention behavior of 10 
immunogenic peptide analogs (pI: 3.7 − 10.1). One was a peptidomimetic related to an HIV-1 
gp120 epitope and the other nine were short synthetic analogs of the parent peptide. The study used 
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a packed fused silica capillary (i.d. 100 µm and a total length 33.5 cm, packed length 25 cm), 
containing 3 µm C18 particles. The impact of mobile phase composition on the separation of these 
peptides was investigated. It was shown that the mobile phase properties, such as pH, buffer 
concentration and the choice and concentration of the organic modifier, can be selected to favor 
either electrophoretic mobility or chromatographic retention. This makes it possible to effect the 
overall selectivity of CEC for the peptides by exploiting both separation mechanisms92. For 
example, at high pHs of the mobile phase, acidic peptides became more negatively charged and 
therefore migrated more rapidly to the anode, thus favoring an electrophoretic mobility separation 
mechanism. However, by adjusting the fraction of ACN within mobile phase, the hydrophobic 
interactions between the n-alkyl ligand of the stationary phase and hydrophobic peptides can be 
exploited. The hydrophobic peptides in the mixture were retained longer on the CEC column at 
lower percentages of ACN. The increase in the fraction of ACN in the mobile phase cause the 
hydrophobic interactions to decrease and thus the electrophoretic mobility of the peptide and the 
EOF becomes the most dominant effect for the migration of both acidic and basic peptides within 
the mixture. 
  
3.4.2.2 Ion-exchange CEC 
3.4.2.2.1 Capillary electrochromatography ion-exchange columns 
Various ion exchange packed CEC columns, have been used for the separation of 
peptides/proteins including strong cation (SCX), strong anion ion-exchange (SAX) columns, weak 
cation exchange (WCX) and weak anion exchange (WAX) columns.  
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A CEC separation of insect oostatic peptides (IOP) was achieved using a capillary packed 
with a strong-cation-exchange stationary phase (3 µm propyl sulfonic acid modified silica 
particles)93. The effect of different experimental parameters (organic modifier, ionic strength, 
buffer pH, applied field strength, and temperature) on the resolution of the IOP peptides was 
evaluated. Baseline separation was achieved using a mobile phase that consisted of 100 mM 
NaH2PO4 buffer (pH 2.3) /H2O/ACN (10:20:70%). The selection of the experimental parameters 
strongly affected the retention factor (k’CEC), retention time and resolution of the analytes. For 
example, ACN content within the mobile phase is known to affect the viscosity, zeta potential, and 
dielectric constant of the mobile phase. By increasing the percentage of ACN within the mobile 
phase from 40 –80%, there was an increase in k’CEC, and improved resolution. The increase in the 
percentage of ACN also enhanced the hydrophilic interactions of the peptides with both the free 
silanol of the fused-silica capillary and sulfonic groups of the stationary phase. On the other hand, 
a higher fraction of ACN enhanced the hydrogen bond interaction between the IOPs and sulfonic 
acid modified silica particles. 
   
3.4.2.2.2 Microchip ion-exchange electrochromatography 
Although most research articles on CEC that have been published deal with packed 
capillaries, there are a limited number of articles that focus on the packing and different 
applications of CEC with a microchip system 94-96. This is mainly due in part to the difficulty of 
packing microfluidic channels with stationary phase materials 96. Microfluidic chip-based bead-
packed columns for electrochromatography have been used with several types of stationary phases 
such as silica colloidal beads 94 and octadecylsilane-coated silica beads97. One example is a 
fabrication of microchip electrochromatography chips with columns of only 2 mm in length. These 
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micro-fabricated devices were then used for the separation of FITC-labeled peptides by ion-
exchange using a 488 nm Ar ion laser for LIF detection. A mixture of three FITC labeled peptides 
(FITC-dilysine, -trilysine, -tetralysine) was separated using  strong cation-exchange beads (Pheno 
Sphere®SDX), and a BGE that consisted of 60 mM KH2PO4/ ACN/ tween 20 [60: 40: 0.025]. The 
peptides were baseline resolved with separation efficiencies of up to 400,000 N/m and run times 
of less than 40 s. The retention times of the three separated peptides were reproducible (RSD <3%) 
95.  
 
3.4.2.3 Specially packed CEC stationary phases 
Enantioseparation of amino acids and dipeptides can be accomplished with a packed CEC 
column with silica-based ligand-exchange chiral stationary phases (CSPs) 98. These CSP CEC 
column were prepared by two different approaches. The first involved a dynamic coated layer of 
the chiral selector N-decyl-L-4-hydroxyproline onto an RP packed capillary. The other approach 
involved chemically bonding L-4-hydroxyproline to 3 μm silica material. Better resolution for the 
enantioseparation of amino acids and dipeptides of enantiomer mixtures was obtained using a 
chemically bonding method compared to the dynamic coated method 98. 
Liao et. al. 99 were able to develop a rapid one-step approach for the preparation of anti-
voltage photonic crystals (PCs) as a stationary phase within a microchip channel. This is frequently 
a time-consuming method that requires many steps. The heat-accelerated one-step approach 
produced a crack-free and stable PCs stationary phase within the channels within 15 mins. Figure 
13 illustrates the PC assembly process. By using these PCs and a BGE of 20 mM NaB4O7 (pH 
10.02) and a field strength of 1000 V/cm, they were able to separate a mixture of three FITC 
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labeled amino acids in 4 s and a mixture of four FITC labeled oligoglycin peptides in 12 s [Figure 
14]. This was accomplished using a microchip with a channel with an effective length (LD) of 2.5 
mm and total length (LT) of 1cm. These separations exhibited good reproducibility of migration 
times (RSD 0.24%–0.35%) and peak heights (RSD 1.1%–3.1%).  
    
 
Figure 13: Flowchart showing (a) the assembly of stable PCs into glass MC channels by (b and c) 
heating with a hot air flow to accelerate the evaporation-induced assembly (b) and to 
fix the assembled ends (b and c). The fixed PCs was used after the removal of the 





Figure 14: Separation of (a) FITC-labeled amino acids at 1200 V cm−1 (b), FITC-labeled 
peptides at 1000 V cm−1. BGE: 20 mM Na2B4O7 at pH 10.02. The LD and LT were 
2.5 mm and 1 cm, respectively99. (Reprinted with permission) 
 
3.4.3 Porous polymer monolith CEC 
Porous polymer monoliths (PPM) have rapidly grown in popularity as stationary phase 
materials for the separation of protein and peptides by CEC. A major reason for this is that the 
packing of narrow diameter capillaries with particles can be a multi-step process that requires 
considerable skill to obtain stable columns with reproducible properties. In addition most packed 
CEC columns require frits that add to the difficulties of manufacturing these columns. Monolithic 
columns can be prepared directly within a capillary or microchip, thus avoiding difficulties seen 
with the packing of capillaries and frit formation. 
For the production of monolithic columns, a simple in situ polymerization process can be 
performed directly within the capillaries, thus avoiding packing and frit formation difficulties. 
Monolithic columns can also be produced with unique chromatographic properties for optimal 
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resolution and efficiency in protein/ peptide separations. The PPMs are covalently bonded to the 
capillary wall by the use of adhesion promoter such as 3-(trimethoxysilyl)propyl methacrylate. 
This increases the column robustness.  
The chemical properties of the PPM can also be controlled by optimizing the composition of 
the polymerization mixture. The polymerization mixture is composed of monomers, an initiator, 
and a porogenic solvent. Materials used as monomers include polar materials, such as 2-
cyanoethylacrylate 100, acrylamide, 2-hydroxyethylmethacrylate 101, and 2-acrylamido-2-methyl-
1-propanesulfonic acid 102. Nonpolar materials such as butylmethacrylate 102, hexylacrylate 103, 
lauryl methacrylate and octadecylmethacrylate 104; and cross-liker such as ethylenedimethacrylate 
105 can also be used.  Initiators, such as azobisisobutyronitrile (AIBN) 106, are frequently used in 
monolith production. Polymerization reactions can be initiated either thermally or by UV-initiated 
free radical polymerization 107-108.  Different porogenic solvents with a range of polarity have been 
used in the preparation of PPM such as 2-propanol 109, 1-octanol 110, 1-dodecanol, and toluene 107. 
The porogenic solvents have an effect on the pore size within the PPM structure. Monolithic 
structures with small microglobules (due to numerous nuclei that are formed within polymerization 
mixture) and small pores may be formed using porogenic solvents with low polarity. In contrast, 
the use of porogen solvent with a higher polarity can lead to the formation large size pores within 
the structure of the PPM capillary 111.  
 
3.4.3.1 RP CEC monolithic column 
To reduce electrostatic interaction of analyte to the monolithic columns, Karanfa and El Rassi 
112 developed multiple versions of a neutral, reverse phase monolithic columns for CEC 
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separations of proteins/peptides. One example of a column used in their work is a reverse phase 
hydroxylated octadecyl monolithic column (ODM-OH). This monolithic column was prepared by 
first pre-treating the capillary with 3-(trimethoxysilyl)propyl methacrylate, followed by the 
polymerization mixture of octadecyl acrylate (ODA) as the monomer and pentaerythritoltriacrylate 
(PETA) as the crosslinker. AIBN was used as the thermal initiator.  An aqueous porogenic solvent 
that contained cyclohexanol and ethylene glycol was used in the fabrication of the column. The 
monolithic column produced a cathodal EOF over a range of pHs, despite not having a full charge.  
The EOF was reported to be due to the polar OH functional group on PETA lead to an increase of 
the surface polarity of the monolith and thus an increase in the zeta potential and resulted in an 
enhancement of the EOF. 
The monolithic column was used for the separation of a mixture of the following proteins (pI 
4.2-11): lysozyme, cytochrome c, carbonic anhydrase, β-lactoglobulin B, β-lactoglobulin A, and 
α-lactalbumin. The mobile phase used was 10 mM sodium phosphate (pH7) containing 50% ACN. 
The proteins eluted in order of pI, with lysozyme (most basic) eluting first and α-lactalbumin (most 
acidic) eluting last. All six proteins eluted in 11.5 min and the average number of theoretical plates 
was calculated to be 201,000 N/m. They also were able to use the developed ODM-OH column to 
separate a complex tryptic protein digest of chicken egg white lysozyme, that would have 
otherwise required a lengthy gradient elution method with LC. 
 
3.4.3.1 Ion-exchange CEC monolithic column 
Ludewig et.al 113 reported the use of a weak-ion exchange (WCX) monolithic column for the 
separation of mixtures of diastereomers and α/β-isomers of α/β-D/L-Asp-L-PheOMe, L-Phe-α/β-
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D/L-Asp-GlyOH and L-Phe-α/β -D/L-Asp-GlyNH2. The column was produced by first pre-
treatment of the capillary with 3-(trimethoxysilyl)propylmethacrylate followed by in situ 
polymerization of acrylamide, 4-acrylamidobutyric acid and methylenebisacrylamide and AIBN 
with decanol and DMSO as porogen solvent. The research studied the effect of the pH of the 
mobile phase on the mobility of the peptides and their separation. With acidic mobile phases 
containing ACN, the peptides are protonated and migrated mainly due to their electrophoretic 
mobility. At a more basic pH, the peptides have lower mobility due to deprotonation of the 
carboxylic acid groups and amines. However, increasing the pH of the mobile phase also caused 
an increase in the EOF due to an increase in the number of deprotonated carboxylic acid groups 
on the monolith. This also effected the elution of the peptides. The WCX monolithic columns was 
used to separate the diastereomers L-Phe-α/β-D/L-Asp-GlyOH with a mobile phase consisting of 
20 mM phosphate buffer, pH 2.0 and 40% v/v ACN. The WCX monolithic column provided added 
selectivity and separation mechanisms, as the separation of all diastereomers of L-Phe- α/β -L/D-
Asp-GlyOH, could not be achieved by CE nor LC. 
  
3.4.4. Open tubular CEC 
Open-tubular capillary electrochromatography (OT-CEC) was first reported in 1982 by 
Tusda et. al. 114. He developed OT-CEC for the separation of aromatic compounds (benzene, 
biphenyl, naphthalene, anthracene, and 1,3,5-triphenylbenzene). Since then research on OT-CEC 
has focused mainly on the development of materials that can be used as stationary phases for the 
coating onto the inner wall of fused silica capillaries. Stationary phase materials are selected to 
improve selectivity based on the preferred chromatographic mechanisms. Materials with various 
chemical and physical properties can be used as components of the stationary phase such as long 
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non-polar hydrocarbon chains e.g. 1-octadecanethiol 115, high molecular weight charged polymers 
(e.g. polydiallyldimethylammonium chloride (pDDA) or polydopamine) and functionalized 
nanoparticles (e.g. β−cyclodextrin modified gold nanoparticles OT-CEC columns 116 or magnetic 
nanoparticle OT-CEC columns 117). Advantages of OT-CEC over other CEC methods including 
ease of preparation. OT-CEC does not require particle−based packing materials or frits to keep the 
OT-CEC layer in place 118. However, due to the low amount of stationary phase that is coated onto 
the inner surface, the phase ratios are small, which leads to low retention of the analytes. This can 
cause decreased selectivity for the separation of some analyte compared to packed CEC 119.  
An important part of OT-CEC system is the stationary phase that coats the inner capillary 
wall. Two main factors affect the robustness of the stationary phase in OT-CEC. The first is the 
method of how the coating material is introduced, and the second is the stability of coating material 
under various separation conditions or after repeated electrophoresis runs. Recently, a variety of 
materials and coating approaches have been reported for OT-CEC column, improving both peak 
efficiency and resolution for the analysis proteins/ peptides. Table 3 lists examples of stationary 




































































































































































































































































3.4.4.1 Covalent modification methods 
Covalently bonding the stationary phase materials to the silanol groups of a fused silica 
capillaries inner wall has also been used to produce OT-CEC columns.  Although this approach 
produces a stable coating with longer lifetimes in comparison to physical coating methods, it 
frequently requires a more complex coating procedure 127. The stable coating provided by covalent 
bonds is preferred for some detection systems such as electrospray mass spectrometry (ESI−MS) 
where nonstable coatings, such as dynamic coating systems, may be incompatible. Ramsey’s group 
128 developed a microfluidic system coupled to ESI-MS, where the glass device was first coated 
with 3-(aminopropyl) di-isopropyl-ethoxysilane by chemical vapor deposition. This was followed 
by a covalent coating of the injection cross and separation channels with methyl-terminated 
polyethylene glycol n-hydroxy succinimide ester (NHS-PEG450) via liquid phase PEGylation. The 
device was used for the separation of intact monoclonal antibodies charged variants [Figure 15]. 
A more complex coating method was developed by Aydoğan et.al. that uses a multistep 
process for the preparation of a tentacle-type polymer stationary phase attached to a 
polyethyleneimine (PEI) anion exchanger 129. This column was used for the separation of three 
basic proteins (ribonuclease A, cytochrome c and myoglobin). The preparation procedure included 
initial silanization of the inner wall of a fused silica capillary. This was then followed by in situ 
graft polymerization with 3-chloro-2-hydroxypropyl methacrylate (HPMA−Cl) and PEI 
modification. The modified column provided a high anion exchange capacity, leading to 
enhancements in both retention and resolution for the separation of the three proteins. Baseline 
separation of all three peptides with theoretical plate numbers of 134,000 N/m was achieved by 







Figure 15: A) Schematic for CE-ESI devices with a 23-cm separation channel with an enlarged 
image of the asymmetric turn tapering. B) Separation of intact Infliximab charge 
variants using a 23-cm APS-PEG450 coated device at approximately 600 V/cm. 




column was also shown to be stable for multiple runs with reproducible retention times for the 
separated proteins (SD of < 2%).  
A less complicated method for preparation of OT-CEC column is to use in situ 
polymerization in the presence of porogen solvents. This forms a porous inner surface wall onto a 
capillary pretreated with γ-methacryloxypropyltrimethoxysilane. The porous polymeric layer 
stationary phase shows excellent mass transfer, due to a large number of micropores and 
mesopores on the porous surface, leading to enhanced resolution for protein/peptide separations. 
One example of the application of this method is the separation of cytochrome c and bovine serum 
albumin using a porous inner surface wall coated capillary made from a mixture of butyl 
methacrylate, ethylene glycol dimethacrylate, 2-acrylamido-2-methylpropanesulfonic acid and 
azobisisobutyronitrile and 1-propanol was used as the porogen solvent 130. 
 
3.4.4.2 Nanoparticles coating approaches 
Nanoparticles (NPs) are known to have unique physical and electrical properties. NPs have 
been frequently used in electrophoresis separation methods 131-132. NPs have been used for 
stationary phases in OT-CEC to increase the surface area of the capillary inner wall. The large 
surface area to volume ratio of NPs can improve the chromatographic capacity of CEC. An 
advantage of the using nanoparticles in CEC is that selectivity and resolution may be improved by 
controlling the NPs size, shape, and capping agent. Also, NPs can easily be modified with a variety 
of functional groups that can include thiols, amines or carboxyl groups 133-134. All these parameters 
will influence the interaction of specific analytes with the NPs.  
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Due to the advances in NPs synthesis methods, various methods have been found for the 
preparation of NPs. One of the most widely used methods for the preparation of gold nanoparticles 
(GNPs) is the Turkevich method, as GNPs can be prepared by chemical reduction of gold(III) 
chloride hydrate by sodium citrate. Miksik et. al. 135 were able to prepare a GNPs-based stationary 
phase that was used as an OT-CEC column. The column was prepared by rinsing a pretreated sol-
gel column, with a solution of GNPs (prepared by Turkevich method). The research group 
evaluated the OT-CEC column by comparing them with an unmodified fused silica capillary. Both 
GNPs modified and the bare fused silica capillary were used for the separation of a complex tryptic 
digestion of bovine serum albumin (BSA). The GNP modified capillary reported better separation 
efficiency. The group also investigated different experimental parameters, such as BGE 
concentration and pH, on the separation efficiency and resolution. They reported the best 
separations of the tryptic peptides were found using a BGE consisting of 100 mM sodium 
phosphate buffer (pH 2.5), at a field strength of 175 V/cm (LT 57 cm, LD 47cm, and id 50 μm). 
  Another approach regarding nanoparticles for CEC involves the study of the effect of 
citrate stabilized gold nanoparticles coated capillary compare to bare fused capillary, for the 
analysis of a complex mixture of tryptic peptide fragments of human serum albumin (HSA). The 
immobilized GNPs OT-CEC column was prepared by rinsing a solution of GNPs to a surface 
modified capillary, that was pretreated with 3-aminopropyltriethoxy silane. The study has shown 
an improved resolution of HSA fragments by using GNP coated capillary 136. Table 4 shows other 





















































































































































































































































































































































3.4.4.3 Noncovalent coating method 
Unlike other capillary coating methods used in OT−CEC, noncovalent coating has the 
advantage of being relatively easier to produce than covalent coatings, with a minimum amount of 
time spent for the preparation of the OT-CEC column. Based on the stationary phase materials 
used, noncovalent coating can incorporate and mixture of electrostatic or hydrophilic interactions. 
 
3.4.4.3.1 Static coating 
This approach of coating involves a strong physical adsorption of the coating materials 
onto the inner wall of fused silica capillary. Although, the coating material is not required to be 
within the background electrolyte, the coated stationary phase should be stable for a number of 
runs and regeneration of the coating surface may be required after repeated runs. The removal of 
the coating material from the capillary may require a complex rinsing method.  Materials that are 
most commonly used for static coating are long chain polymers. The advantage of static coating 
over covalent coating is the ease of the coating method, the minimal surface chemistry adaptation 
required for the coating process, and the possibility of the coating regeneration of capillaries. The 
adsorbed materials used for capillary coating can be neutral or positive molecules, as well as 
multilayers of alternating negatively and positively charged polymers [Figure 16].  
There has been continuous research regarding the development of coating materials for 
static coating in OT-CEC. For example, Ullsten et.al. 141 synthesized a novel quaternary 
ammonium substituted agarose polymer (Q-agarose) [Figure 16]. The synthesized cationic 
polymer was coated onto the inner surface of a negatively charged fused silica capillary via multi-
site electrostatic interaction. The coated capillary produced an intermediate anodal EOF over the 
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pH range of 2-11and was reported to be stable and exhibit reproducible analyte migration times 
(RSD 4%). The capillary coating repelled moderately basic proteins/peptides, giving separation 
efficiencies of up to 300,000 N/m.  
 
  
Figure 16: Chemical structure of various polymers used in OT-CEC: A) 
polydiallyldimethylammonium chloride (pDDA), B) polybrene (PB), C) 
polystyrene sulfonate, D) Q-agarose, E) dextran sulfate. 
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Multilayer coating methods are also popular for protein/peptide analysis using OT-CEC. 
The layers are held together mainly by electrostatic interactions. The desired thickness, charge, 
and function of the modified wall is a function of the number of coating cycles used to form the 
OT−CEC. Successive multiple ionic-polymer layer (SMIL) coating has the advantage not only of 
high stability after repeated use, but also many columns are stable in both strongly basic (1 M 
NaOH) and strongly acidic (1M HCl) solutions. A polybrene (PB)-modified capillary has been 
demonstrated to improve the separation of model proteins in comparison to that obtained with a 
bare fused silica capillary. Production of the PB capillary was achieved by a 15-min rinse with 
10% PB solution to form the first layer (cationic), this was followed by 15 min rinse of an anionic 
polymer such as dextran sulfate or hyaluronic acid, to form the second layer. Finally, the capillary 
was once again rinsed with 10% PB solution over 15 min to form the third and final layer. The 
(PB)−modified capillary was used for the successful analysis of four basic proteins (α-
chymotripsinogen A, ribonuclease A, lysozyme, and cytochrome c), wherein the case of the 
uncoated capillary, the proteins did not elute due to irreversible adsorption to the capillary wall 142. 
 
3.5 Conclusion 
Capillary electrochromatography methods have shown to be an ideal analytical technique 
for the analysis of proteins/ peptides. Compared to CE and ME, the added stationary phases can 
improve both separation efficiency, selectivity, and resolution for certain analytes. This is due to 
the reduction of the nonspecific analyte-wall adsorption and increase in analyte partition between 
CEC stationary phase and mobile phase respectively. However, there are some disadvantages 
associated with CEC.  Most forms of CEC are a time-consuming and labor-intensive method for 
the production of the CEC column. The packaging or covalently bonding of the stationary phase 
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of CEC capillary columns often involves multiple steps. Also, under some conditions, packed CEC 
columns can exhibit difficulties with obtaining a stable current due to the formation of air bubbles 
at the packing materials and the frits. Other disadvantages of CEC stationary phase materials are 
that many are pH sensitive, with a narrow pH range that CEC column can be used for protein and 
peptide analysis.  
The use of OT-CEC eliminated problems related to packed CEC. With recent 
developments in OT-CEC columns, different materials such as long chain charged polymers or 
nanoparticles that are functionalized with various chemical groups could be used to improve CEC 
analysis of therapeutic proteins or proteins/ peptides that can be used as disease markers such as 
elevated levels of the dynorphin A. 
Chapter 4 presents the use of CEC column coated with gold nanoparticles for the separation 
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Dynorphin A (Dyn A) is an endogenous opioid peptide that is derived from the precursor 
peptide preprodynorphin1-2. This peptide has high affinity for the κ opioid receptor3. Dyn A has 
been found to exhibit both antinociceptive and analgesic effects within the central nervous system4 
and is also involved in the body's immune response as well as cardiovascular and temperature 
regulation5. However, upregulation of Dyn A due to pathophysiological states (neurotrauma, 
neurodegeneration, or drug abuse) has been shown to cause nonopioid activity such as 
hyperalgesia, allodynia, and excitotoxicity6. These activities are mainly glutamatergic, and are 
mediated through the N-methyl-D-aspartate receptor7-9. Dyn A's toxic effects have been linked to 
neurotoxicity and cell death7, 10. 
Capillary electrophoresis (CE) can provide high separation efficiencies and short analysis 
times. It also requires low sample volumes and small amounts of run buffer11. However, one 
limitation for the analysis of proteins and peptides with high pI values is the adsorption of these 
species onto the inner surface of fused-silica capillaries, due to their interaction with ionized silanol 
groups12. This adsorption can lead to a loss of separation efficiency, irreproducibility of migration 
times, and peak tailing13-15. Coating of the inner surface can decrease the amount of adsorption of 
analytes onto fused-silica capillaries16. The capillary coating can be either produced by covalent 
or physical bonding. Although the use of a permanent covalent coating does provide a more stable 
and reproducible EOF, preparation of these capillaries can be tedious and time-consuming16. 
Physical coating using polycharged polymers, for example polydiallyldimethylammonium 
chloride (pDDA), can produce a stable surface, although the bonding strength is weaker than that 
of covalent bonding17. These large polycharged molecules offer several bonding sites to the 
capillary wall, ensuring a stable coating16-17. Unfortunately, improving the separation through the 
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modified surface is limited to a uniform (flat) surface and the chemical stability of the coating 
material18. Gold nanoparticles (GNP), due to their unique chemical and physical properties, are 
another material that has been used to coat capillaries for peptide and protein CE separations19-22. 
An advantage of using nanoparticles in CE is that selectivity can be improved by controlling the 
size, shape, and type of coating used on the gold particle. All these parameters will influence the 
interaction of specific analytes with the GNP. The GNP also provide a greater surface area for 
these interactions compared to modified silica capillaries. Capillaries coated with citrate23, 
didodecyldimethylammonium bromide24, and octadecylamine25 capped GNP have been reported 
previously for CEC. Recently, Zhang et al.26 reported a separation of heroin and basic impurities 
using GNP that were stabilized using a cationic polymer of a quaternary ammonium salt pDDA 
(pDDA-GNP). 
The aim of this work was to evaluate GNP for the separation of the opioid peptide Dyn A(1–
17) and its metabolites [Table 1] using a CEC capillary coated with pDDA-GNP. It was shown 
that the pDDA-GNP were able to reduce the electrostatic undesirable adsorption of these positively 




Table 1: Structure and pI of all eight opioid peptides used in this study.  
Peptide Structure M.W. (g/mol) pI 
Dynorphin A 1-17 YGGFLRRIRPKLKWDNQ 2147.52  11.41 
Dynorphin A 2-17 GGFLRRIRPKLKWDNQ 1984.34 12.13 
Dynorphin A 1-13 YGGFLRRIRPKLK 1603.98  12.13 
Dynorphin A 1-11 YGGFLRRIRPK 1362.65  12.12 
Dynorphin A 1-8 YGGFLRRI 981.17 11.13 
Dynorphin A 1-7 YGGFLRR 868.01  11.13 
Dynorphin A 1-6 YGGFLR 711.82  9.84 
Leu-enkephalin YGGFL 555.63  5.93 
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4.2 Materials and methods 
4.2.1 Reagents and chemicals 
Dyn A(1–17), Dyn A(2–17), Dyn A(1–13), Dyn A(1–8), and Dyn A(1–7) were purchased 
from Biomatik (Cambridge, ON, Canada). Dyn A(1–6) and Dyn A(1–11) were purchased from 
Shanghai MoCell Biotech (Shanghai, China). Leu-enkephalin (Leu-ENK) was received from Alfa 
Aesar (Ward Hill, MA, USA). Gold (III) chloride hydrate, 20% polydiallyldimethylammonium 
chloride (M.W. 200,000–350,000 Da) solution, sodium acetate trihydrate, sodium phosphate 
monobasic, sodium phosphate dibasic, and β-cyclodextrin (β-CD) were received from Sigma–
Aldrich (St. Louis, MO, USA). Acetic acid, hydrochloric acid, methanol, and sodium hydroxide 
(molecular biology grade >98%) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
Sequencing grade-modified trypsin was purchased from Promega (Madison, WI, USA). All water 
used was Milli-Q grade (resistivity of 18 MΩ). Aqueous filter membranes (0.45 μm) were 
purchased from Fisher Scientific. Polyimide-coated fused-silica capillaries 75 μm id, 375 μm od 
were received from Polymicro Technologies (Phoenix, AZ, USA). 
 
4.2.2 Equipment 
Analyses were performed on a Beckman Coulter P/ACE MDQ (Brea, CA, USA) CE 
system with a UV detector operating at 214 nm. Polyimide-coated fused-silica capillaries 75 μm 
id, 375 μm od (Polymicro Technologies) were employed in the study. The total length of the 
capillaries (unless stated otherwise) was 49 cm, the effective length (from injection to detector) 
was 39 cm. A 0.5 cm detection window was made by burning off the outer polyimide capillary 
coating with Window Maker® (Eatontown, NJ, USA). Samples were introduced using 
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hydrodynamic injection by applying 0.5 psi head pressure for 5 s. Electrophoretic separations were 
performed at applied voltage of (±) 10–20 kV. Following each run, the fused silica capillaries were 
rinsed with 0.1 M NaOH, water, and BGE for 3 min each. Modified capillaries were rinsed with 
BGE for 3 min before each sample injection. Data were recorded using the 32 Karat software 
(Beckman Coulter). 
 
4.2.3 Synthesis of pDDA-stabilized GNP 
PDDA-stabilized GNP were synthesized based on the method described by Chen et al.27. 
A solution of 250 μL of the polymer (4% pDDA solution), 200 μL of 0.5 M NaOH, and 100 μL 
AuHCl4(10 mg/mL) in 40 mL of Milli-Q water was brought to boiling under vigorous stirring. The 
solution gradually turned from a colorless solution to a wine-red color [Figure 1]. When no more 
color change was observed, the heat was removed and the solution was left to stir at room 
temperature for an additional 15 min. The size and shape of the GNP were confirmed using 
transmission electron microscopy [Figure 2]. 
 
4.2.4 Preparation of buffer and standard solutions 
A stock solution of 100 mM sodium acetate buffer (pH 5) was prepared using sodium 
acetate trihydrate and acetic acid. The pH was adjusted using 1 M sodium hydroxide or 1 M 
hydrochloric acid. The BGE used for CE was achieved by further dilution of the stock solution 
and was filtered through a 0.45 μm membrane filter before use. For the GNP-modified capillary, 
5% v/v pDDA-GNP was added to the BGE. A tryptic digest of Dyn A(1–17) was prepared as 




Figure 1: The proposed electrostatic interaction of AuCl4




Figure 2: Transmission Electron Microscope (TEM) image showing size and shape of pDDA-






enzyme:substrate ratio of 1:150 (mass/mass). The sample was then incubated at 37°C for up to 9 
h. Small aliquots of the studied solution were collected hourly and then further diluted in the BGE. 
 
4.2.5 Capillary column coating procedure 
All solutions used for the modification of the capillary were freshly prepared. New fused-
silica capillaries were preconditioned by rinsing for 5 min each with 0.1 M HCl, water, methanol, 
water, 0.1 N NaOH, water, followed by a 10-min rinse with the BGE. The pDDA coating was 
done by rinsing the capillary with 0.1 N NaOH for 5 min followed by H2O for 5 min; this was 
followed by rinsing the capillary 0.2% pDDA solution for 30 min and then rinsing the capillary 
with 0.02% pDDA in BGE for 10 min. A −12 kV potential was applied across the capillary for 10 
min following the conditioning for equilibration of the BGE within the pDDA-coated capillary. 
The pDDA-GNP coating procedure was as follows. The process was started by rinsing the 
capillary with 0.1 N NaOH for 20 min followed by H2O for 15 min to ionize the silanol groups on 
the capillary surface. The capillary is then rinsed with (1:1) pDDA-GNP solution for 15 min, and 
the solution was held within the capillary for an additional 15 min (total 30 min). Next, the 
capillary was washed with H2O to remove any excess unadsorbed GNP on the capillary surface. 
Finally, the modified capillary was rinsed with BGE for 15 min. A −12 kV potential was applied 
across the capillary for 10 min following the conditioning for equilibration of the buffer within the 
modified capillary [Figure 3]. Before each electrophoresis run, the modified capillary was rinsed 
with BGE for 3 min. The GNP-coated capillary was conditioned each day by rinsing with BGE 
for 10 min. Whenever changes of BGE components were required, the capillary was reconditioned 
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with the new BGE for 10 min. For overnight storage, the modified capillary was rinsed with Milli-
Q water for 10 min and then stored in water. 
 
4.2.6 Electrophoresis procedure 
Stock solutions of the peptides Leu-ENK, Dyn A(1–17), and the Dyn A(1–17) fragments 
Dyn A(1–6), Dyn A(1–7), Dyn A(1–8), Dyn A(1–11), Dyn A(1–13), and Dyn A(2–17) were 
prepared in Milli-Q water at a concentration of 1 mg/mL and stored at −20°C in polypropylene 
microcentrifuge tubes. The peptides were then diluted to the required concentrations using the 
same BGE for each run. Samples were injected by applying 0.5 psi head pressure for 5 s. The 
separation voltage was between 12–20 kV in either normal or reverse polarity depending on 
capillary charge surface. To evaluate different electrophoresis conditions, five representative 
peptides—Leu-ENK, Dyn A(1–6), Dyn A(1–7), Dyn A(1–8), and Dyn A(1–11)—were chosen. 
These peptides mainly differ structurally in the number of cationic residues and size. Leu-ENK is 
neutral at pH5 and was used for the measurement of the EOF. In addition, a mixture of Dyn A(1–
17) and seven other peptide fragments (Leu-ENK, Dyn A(1–6), Dyn A(1–7), Dyn A(1–8), Dyn 
A(1–11), Dyn A(1–13), and Dyn A(2–17)) was separated using pDDA-GNP-coated capillaries. 
 
4.3 Results and discussion: 
4.3.1 Separation of opioid peptides using unmodified fused silica 
The separation of the mixture of the five opioid peptides was first attempted using an 






Figure 3: Illustration showing the interaction of capillary wall with A) a monolayer of 










separation voltage was +12 kV using a capillary having a total length of 39 cm. Under these 
conditions, no peaks were observed in the electropherogram, most likely due to the irreversible 
adsorption of the peptides onto the surface of the fused-silica capillary.  
 
4.3.2 Separation of opioid peptides using a pDDA-coated capillary 
The peptide mixture was then injected into a capillary coated with the cationic polymer 
(pDDA). This positively charged polymer adsorbed onto the negatively charged capillary wall, 
creating a positive surface. The excess positive charges from the polymer generated a significant 
EOF toward the anode (EOF = −5.2 × 10−4 cm2/Vs). The surface also repelled the positively 
charged peptides and blocked the ionized silanol groups, thereby inhibiting adsorption of these 
peptides to the capillary wall. 
Figure 4A shows the electropherogram obtained for the separation of five opioid peptides, 
Leu-ENK, Dyn A(1–6), Dyn A(1–7), Dyn A(1–8), and Dyn A(1–11). A BGE consisting of 20 mM 
sodium acetate buffer (pH 5) containing 0.02% v/v pDDA and a separation voltage of 15 kV 
(reverse polarity) was used. The separation of all five peptides was accomplished in <9 min with 
detection at the anode. The order of migration was Leu-ENK, Dyn A(1–6), Dyn A(1–8), Dyn A( 
1–7), and finally, Dyn A(1–11). The resolution between each peak and its neighboring peak was 
calculated. For the peptides Leu-ENK, Dyn A(1–6), Dyn A(1–8), Dyn A(1–7), and Dyn A(1–11), 
R values were calculated to be 9.4, 6.93, 1.93, and 11.4, respectively. The migration order was 
predicted as follows: Leu-ENK is neutral at pH 5 and, therefore, migrated first. The remaining four 
dynorphin peptides all have one or more arginine groups in their chemical structures. Dyn A(1–





Figure 4: Separation of (1) Leu-ENK, (2) Dyn A(1–6), (3) Dyn A(1–8), (4) Dyn A(1–7), (5) Dyn 
A(1–11).  A) pDDA-modified capillary [BGE: 20 mM sodium acetate containing 
0.02% pDDA (pH 5)]; B) pDDA-GNP-modified capillary [BGE: 20 mM sodium 
acetate containing 5% pDDA-GNP (pH 5)]. HV: –15 kV, LT = 49 cm, LD = 39 cm, id 









number of arginine groups in their structures, the extra isoleucine group of Dyn A(1–8) led to an 
overall lower charge-to-size ratio and faster migration than for Dyn A(1–7). 
 
4.3.3 Separation of opioid peptides using pDDA-GNP-coated capillary 
Figure 4B shows an electropherogram for the separation of the same five peptides using 
the pDDA-GNP-coated capillary. In this case, the BGE consisted of 20 mM sodium acetate buffer 
(pH 5) containing 5% pDDA-GNP. The GNP-coated capillary exhibited a very fast anodal EOF 
separation (EOF = −6.3 × 10−4 cm2/Vs), which is 20% greater than with a pDDA-coated capillary. 
We believe the pDDA-GNP adsorbed onto the capillary wall increased the surface area of the 
modified capillary surface, generating a larger net positive charge. The high EOF provided shorter 
analysis time and improved peak symmetry, with no change in the separation order from the 
previous method. The resolutions between each peak and its neighboring peak were Leu-ENK and 
Dyn A(1–6) (R = 7.83), Dyn A(1–6) and Dyn A(1–8) (R = 5.31), Dyn A(1–8) and Dyn A(1–7) (R 
= 1.4), and finally, the resolution between Dyn A(1–7) and Dyn A(1–11) was calculated to be R = 
8.71. The EOF measured for pDDA-GNP-coated capillaries exhibited a notable same-day 
reproducibility (%RSD) of 0.76% and a between-day reproducibility of 1.68%. The pDDA-GNP 
capillaries were stable for several days, and the same capillary could be reused for up to 72 runs. 
We never had to discard a capillary due to instability. 
 
4.3.4 Effect of BGE concentration 
Different concentrations of sodium acetate—10, 20, 30, 40, and 50 mM (pH 5) containing 
a constant amount of GNP—were studied with the goal of improving resolution between each of 
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the five peptides Leu-ENK, Dyn A(1–6), Dyn A(1–7), Dyn(1–8), and Dyn(1–11) [Figure 5]. The 
increase in salt concentration lowers the double-layer thickness and zeta potential, leading to 
slower EOF. Higher concentrations of sodium acetate in the BGE produced an improvement in the 
separation of all five peptides, but at the expense of longer run times.  
 
4.3.5 Effect of capillary length 
The effect of capillary length on the separation was evaluated in an attempt to improve the 
resolution of Dyn A(1–7) and Dyn A(1–8). Using a constant field strength of –306 V/cm, two 
capillary lengths were evaluated one with a total length of 39 cm and an effective length of 29 cm 
and a second with a total length of 49 cm and an effective length of 39 cm. The increase in capillary 
length led to an improvement in resolution, with an increase in the overall migration times of all 










Figure 5: The effect of BGE concentration [sodium acetate 10–50 mM, each containing 5% 
GNP (pH5)] on separation of Leu-ENK, Dyn A(1–6), Dyn A(1–8), Dyn A(1–7), and 
Dyn A(1–11). GNP-modified capillary; HV: –15 KV, LT = 49 cm, LD = 39 cm, id= 75 








Figure 6: Effect of capillary length of GNP-modified capillary on separation of (1) Leu-ENK, (2) 
Dyn A(1–6), (3) Dyn A(1–8), (4) Dyn A(1–7), (5) Dyn A(1–11). Field strength –306 
V/cm. A) LT = 39 cm, LD = 29 cm, id = 75 µm, B) LT = 49 cm, LD = 39 cm, id = 75 µm. 
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4.3.6 Effect of organic solvent and BGE additives 
Methanol was then evaluated as an organic modifier in an attempt to improve the resolution 
of Dyn A(1–8) and Dyn A(1–7). Organic modifiers can reduce EOF due to their low dielectric 
constants28. Methanol was added to the BGE at a final concentration of 10% v/v. The effect of 
methanol on the separation is shown in figure 7. The two peptides exhibited longer migration 
times, and there was some improvement in resolution (R = 2.15) compared to BGE without 
methanol (R = 1.89). In a previous report, Zhang et al. [26] studied the influence of adding 
methanol as buffer additive. They found that concentrations <10% in the BGE caused instability 
of the separation current. Higher concentrations of methanol were avoided in these studies since 
too much methanol may adversely affect the stability of pDDA nanoparticle capillary coating.  
A structurally unmodified β-CD was also investigated as a BGE modifier in an effort to 
improve resolution of Dyn A(1–8) and Dyn A(1–7). The concentration of β-CD in the BGE was 
1.5 mM. Peptides with aromatic residues (tyrosine or tryptophan) are known to form inclusion 
complexes with CD29. It was hoped that differences in the overall secondary structure of the two 
peptides could contribute to small differences in the affinities to the β-CD cavity and, thus, improve 
resolution30-32. Unfortunately, there was no substantial improvement in the resolution of Dyn A(1–
8) and Dyn A(1–7) with or without β-CD in the BGE (40 mM sodium acetate containing 5% GNP) 
R = 1.72 and 1.7, respectively [Figure 8]. However, an increase in resolution was seen with a BGE 
having an equal amount of β-CD at a higher sodium acetate concentration (BGE = 50 mM sodium 
acetate, R = 1.78) compared to the lower BGE concentration (20 mM sodium acetate, R = 1.39) 





Figure 7: The effect of 10% (v/v) methanol on the resolution of (1) Dyn A(1–8), (2) Dyn A(1–
7). GNP-modified capillary; HV: –15 kV, LT = 49 cm, LD = 39 cm, id = 75 µm. BGE: 
50 mM sodium acetate containing 5% GNP and 10% CH3OH (pH 5). UV detection λ 














Figure 8: Effect of β-CD as BGE additive on the resolution of (1) Dyn A(1-8) and (2) Dyn A(1-




4.3.7 Separation of metabolites of Dyn A(1–17) 
In vivo enzymatic degradation of Dyn A(1–17) produces fragments of the peptides with 
different pharmacological activity. An attempt to separate a standard mixture of Dyn A(1–17) and 
seven fragments of the opioid peptide (Dyn A(1–6), Dyn A(1–7), Dyn A(1–8), Dyn A(1–11), Dyn 
A(1–13), Dyn A(2–17), and leu-ENK) was studied at concentrations of 20, 40, 60, and 80 mM 
sodium acetate, each containing 5% v/v GNP [Figure 9]. The order of migration of the eight 
peptides was as follows: Leu-ENK, Dyn A(1–6), Dyn A(1–8), Dyn A(1–7), Dyn A(1–17), Dyn 
A(2–17), Dyn A(1–11), and Dyn A(1–13). The optimal BGE was determined to be 40 mM sodium 
acetate [Figure 10]. The calculated resolutions were 9.72, 6.28, 1.69, 1.15, 1.71, 5.8, and 2.55. At 
lower concentrations of BGE, there was a decrease in resolution between Dyn A(1–8) and Dyn 
A(1–7) of 0.86 (peaks 3 and 4) and between Dyn A(1–17) and Dyn A(2–17) a decrease of 0.94 
(peaks 5 and 6). Concentrations higher than 40 mM also showed good separations for both Dyn 
A(1–8) and Dyn A(1–7), but Dyn A(1–7) and Dyn A(1–17) (peaks 4 and 5) comigrated. The 
increase in concentration of the BGE decreased the double-layer thickness, affecting the zeta 








Figure 9: The effect of BGE concentration on separation of pDDA-GNP-modified capillary; 



















Figure 10: Electropherogram showing separation of (1) Leu-ENK, (2) Dyn A(1–6), (3) Dyn 
A(1–8), (4) Dyn A(1–7), (5) Dyn A(1–17), (6) Dyn A(2–17), (7) Dyn A(1–11), and (8) 
Dyn A(1–13). BGE 40 mM sodium acetate containing 5% pDDA-GNP (pH 5). UV 








4.3.8 Separation of tryptic digest of Dyn A(1–17) 
To demonstrate the separation, tryptic peptide fragments of Dyn A(1–17) were analyzed 
using the GNP-coated capillaries. Figure 11 shows an electropherogram of the tryptic digest of 
Dyn A(1–17) at different time points. Peptide fragments were identified based on the migration 
times of the available standards of Dyn A(1–17) fragments. The electropherogram shows a 
decrease in the parent peptide Dyn A(1–17) (peak 4) and the appearance of its tryptic digest 
products Dyn A 1–7 (peak 3) and Dyn A(1–11) (peak 5), which are the N-terminus fragments of 
Dyn A(1–17). Two unknown peaks were also observed at approximately 3.8 and 5.2 min (asterisk). 
We believe the unknown peaks correspond to C-terminus fragments Dyn A(12–17) and Dyn A(8–
17), respectively. This is based on data reported in the literature concerning the identification of a 
tryptic digest of Dyn A(1–17) by LC-MS [33]. However, we were unable to confirm this 
conclusively due to the unavailability of the peptide standard. Using a GNP-coated capillary, we 
were able to follow the progress of the digestion of Dyn A(1–17) by trypsin over time [Figure 11 
and Figure 12]. The GNP-coated capillary was shown to be stable, and can be adapted for the 





Figure 11: Separation of peptides generated by a tryptic digest of dynorphin A(1-17). (A) 0 min, 
(B) 1 h, (C) 3 h, (D) 6 h, (E) 9 h. (1) Dyn A(12-17), (2) Dyn A(8-17), (3) Dyn A(1–7), 
(4) Dyn A(1–17), (5) Dyn A(1–11), based on migration time of standards. (*) Peak 
identity was predicted based on charge and size and migration time. GNP-modified 
capillary; HV = –15 kV, LT = 49 cm, LD = 39 cm, id = 75 µm; BGE: 40 mM sodium 



















CE separations of peptides having a high pI are challenging. This is due to the electrostatic 
adsorption of cationic peptides onto ionized silanol groups in the capillary wall. Here, we have 
developed a method based on the use of pDDA-stabilized GNP as a static coating for the separation 
of Dyn A(1–17) and its biologically active metabolites. The GNP coating acts as a physical barrier 
between the analytes and the capillary wall. In addition, the charge-to-charge repulsion between 
the pDDA-stabilized GNP and cationic groups of the peptide minimizes adsorption of the analyte 
to the capillary wall. Different BGE parameters and additives were evaluated to improve the 
separation of dynorphin and its metabolites. Finally, the approach was demonstrated for a tryptic 
digest of Dyn A(1–17), which was analyzed using pDDA-stabilized GNP-coated capillaries. 
In the future, coupling of pDDA-stabilized GNP-coated capillaries to more sensitive 
detection methods—for example fluorescence or mass spectrometry—to achieve lower levels for 
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Capillary Electrochromatography and Microchip electrophoresis with 





5.1 Introduction  
Capillary electrophoresis (CE) is a separation technique that has shown to be extremely 
useful for the separation of biomolecules. The use of small inner-diameter (i.d.) capillaries in CE 
makes it possible to analyze (submicroliter) small volume samples. However, due to the short path 
length for on capillary detection in CE widely used detection methods, such as UV absorption, do 
not work well for the detection of low concentrations of biologically active peptides. Detection 
limits are generally in the micromolar to submicromolar range1.  
Endogenous concentrations of dynorphins in CNS and blood are in the nanomolar to 
picomolar range. Thus, the detection of these neuropeptides at endogenous levels require more 
sensitive detection methods than UV, such as fluorescence detection. Laser induced fluorescence 
(LIF) detection has been used extensively with CE and microchip electrophoresis (ME) 2-4.  
However, very few peptides exhibit native fluorescence. Therefore, it is necessary to label the 
peptides with a fluorophore to improve the limits of detection (LOD)5 for the analytes. The amine 
groups on peptides can either react either with a dye that is highly fluorescent or with a fluorogenic 
reagent that will then produce a fluorescent product. The fluorogenic labels can also change 
electrophoretic mobility of the analyte, and assist (or make worse) the CE and ME separation. 
Some of the properties of an ideal fluorescence derivatization reagent include a fast reaction rate 
and the formation of a stable fluorescence product that can produce a strong fluorescent signal6. 
Fluorescence derivatization of peptides is frequently accomplished by the reaction of a fluorogenic 
label with amine groups of the peptides, mainly its N-terminus or amine containing residues such 
as lysine or arginine7-8.  
One of the drawbacks of fluorescence derivatization is that many peptides with more than 
one derivatization site, such as peptides with more than one lysine residue, can form multiple 
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products with different degrees of fluorescence labeling9-10 or cause a decrease in fluorescence 
intensity due to intramolecular quenching11. In addition, another downside of fluorescence 
derivatization is that, in some cases, the derivatization reaction rate is slow and may require a high 
peptide concentration for the peptide to be derivatized, where the fluorescent derivatized peptide 
is then diluted to lower concentration for CE-LIF and ME-LIF analysis5. Various functional groups 
within a peptide structure can also alter the reactivity of the primary amine group through inductive 
and steric effects7.   
Naphthalene-2,3-dicarboxaldehyde (NDA) is a fluorogenic reagent that can react rapidly 
with primary amines on amino acids, peptides and proteins in the presence of cyanide ions (CN) 
as the nucleophile, to produce a 1-cyanobenz[f]isoindole (CBI) products [Figure 1A]12-14. 
Favorable properties of NDA include that the probe is not fluorescent, the reaction is reported to 
be rapid, a stable fluorogenic CBI derivative is produced and there is a minimal effect of pH on 
the fluorescent signal intensity12, 15. The CBI fluorescent product has two excitation wavelengths 
in the visible region: (λex) of 420, and 440 nm and an emission wavelength of (λem) ~ 490 nm
16. 
Another widely used reagent for the derivatization of peptides is fluorescein isothiocyanate 
(FITC). FITC is a highly fluorescent reagent. It is known to form FITC fluorescent derivatives by 
reacting with primary amines to produce a fluorescent product. In this case, the excitation 
wavelength is 488 nm and the emission wavelength ~ 520 nm17-18 [Figure 1B].  However, products 
of the FITC reaction can undergo extensive photobleaching, and the fluorescence intensity is pH 
sensitive19. Another disadvantage of FITC labeling is that the reagent itself produces a strong 
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Figure 1: A) The formation of fluorescent CBI derivative by the reaction of NDA with a primary 
amine in the presence of CN. B) The reaction of the fluorescent dye of fluorescein 




 The ability to couple microdialysis (MD) sampling to CE-LIF and ME-LIF offers a method 
to perform online continuous sampling of dynorphins in the brain and spinal cord with high 
temporal and spatial resolution. The use of a slow flow rate (0.1-2 µL/min) in MD sampling is 
preferred for obtaining higher analyte recovery20, which is ideal for the analysis of low 
concertation of bioactive peptides such as dynorphins in the brain. The coupling MD-ME can be 
further developed to undergo on chip fluorescent derivatization and detection using LIF20-21.  The 
ultimate goal of this project is to develop and on-line system for continuous monitoring of these 
peptides in awake freely moving animals to better understand neurodegenerative disease. This 
chapter describes the first steps towards an on-line separation system. Experimental results 
obtained for the development of a separation and detection of derivatized dynorphins by capillary 
and microchip electrophoresis with LIF detection are described. 
 
 5.2 Materials and methods 
5.2.1 Reagents and chemicals 
Dyn A (1–17), Dyn A (1–13), Dyn A (1–8), and Dyn A (1–7) were purchased from 
Biomatik (Cambridge, ON, Canada). Dyn A (1–6) was purchased from Shanghai MoCell Biotech 
(Shanghai, China). Leu-enkephalin (Leu-ENK) was received from Alfa Aesar (Ward Hill, MA). 
Polydiallyldimethylammonium chloride (pDDA) 20% solution with an average molecular weight 
of 200–350 kDa, sodium phosphate monobasic, sodium phosphate dibasic, boric acid sodium 
dodecyl sulfate (SDS) and Brij® 35 were received from Sigma–Aldrich (St. Louis, MO). 
Hydrochloric acid and sodium hydroxide (molecular biology grade >98%), HPLC grade methanol, 
acetonitrile, and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific (Fair Lawn, 
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NJ). All water used was Milli-Q grade (resistivity of 18 MΩ). Aqueous filter membranes (0.2 μm) 
were purchased from Fisher Scientific. Polyimide-coated fused-silica capillaries were received 




Analyses were performed on a Beckman Coulter P/ACE MDQ (Brea, CA) CE system. 
Polyimide-coated fused-silica capillaries 50 μm id, 375 μm od (Polymicro Technologies) were 
employed in the study. The total length of the capillary was 75 cm, the effective length (from 
injection to detector) was 60 cm. A 0.5 cm detection window was made by burning off the outer 
polyimide capillary coating with Window Maker® (Eatontown, NJ). Samples were introduced 
using hydrodynamic injection by applying 0.5 psi head pressure for 5 s. Electrophoretic separations 
were performed at an applied voltage of −20 kV. Following each run, the pDDA modified 
capillaries were rinsed with BGE for 3 min before the next sample injection. Data were recorded 
using the 32 Karat software (Beckman Coulter). 
LIF detection was accomplished using a 442-nm CL-2000 diode laser (Crysta Laser; Reno, 
NV), and monitoring emission data were collected with an external fluorescence detector 
(Picometrics; Ramonville, France). The LIF detector was controlled with 32 Karat software 
(Beckman). 




5.2.2.2 Preparation of buffer and standard solutions 
A stock solution of 200 mM sodium phosphate buffer (pH 6.8) was prepared using sodium 
phosphate monobasic and sodium phosphate dibasic. The pH was adjusted using 1 M sodium 
hydroxide or 1 M hydrochloric acid to the required pH. The BGE used for electrophoresis 
separation was prepared by further dilution of the stock solution to the required concentration. A 
stock solution of NDA was prepared in equal volumes of acetonitrile and water to a final 
concentration of 5 mM. A 20-mM solution of NaCN was prepared in water. Both NDA and NaCN 
solutions were protected from light and stored at 4ºC for a maximum of one week. All BGE 
solutions used were filtered with a 0.2 μm membrane filter before use. Standard solutions of opioid 
peptides used were prepared in H2O to 1 mg/ml, and then further diluted to the required working 
concentration.  
Derivatization of the peptide to produce a CBI-product was accomplished by mixing 15 
µL of 500 µM of the peptide in phosphate buffer (pH6.8) with 25 µL NDA and 10 µL NaCN to 
(approximately ratio of 1: 16: 26 peptide: NDA: CN), and then allowing it to react for 15 mins.  
The solution was then brought to a final volume of 150 µL with phosphate buffer (pH 6.8) and 
injected into the CE.   
The FITC-peptide derivatization was accomplished by slowly adding the florescent FITC 
dye to a solution of 100 μM of the peptide in 100 mM phosphate buffer solution (pH7) at a ratio 






5.2.2.3 Capillary column coating procedure 
All solutions used for the modification of the fused silica capillaries were freshly prepared 
daily. The capillary coating procedure is similar to the method described previously in chapter 4. 
Briefly, a new fused-silica capillary was preconditioned with 0.1 M HCl, followed by water, 
methanol, water, 0.1 N NaOH, finally water for 5 mins each. This was followed by rinsing the 
capillary with 0.1 N NaOH for 5 min followed by H2O for 5 min; this was followed by rinsing the 
capillary 0.2% pDDA solution for 30 min and then rinsing the capillary with 0.02% pDDA in BGE 
for 10 min. A −20 kV potential was applied across the capillary for 10 min following the 
conditioning for equilibration of the BGE within the pDDA-coated capillary.  
 
5.2.2.4 Fabrication of silicon master and PDMS/ glass microchip electrophoresis 
The fabrication procedure for the creation of the silicon master with a simple-t design has 
been described elsewhere22. Briefly, a 4-inch silicon wafer was spin coated with SU-8 negative 
photoresist (thickness 15 μm) using Brewer Science Cee 200CBX spin coater (Rolla, MO). This 
was followed by a soft bake at 65℃ for 2 min then a 5 min bake at 95°C. After the wafer is cooled 
to room temperature, a photomask with the design of the microfluidic channels is placed over the 
negative photoresist coated wafer, and then exposed to UV light using a UV flood source. The 
master is then post-baked at 65°C for 1 min, then 95°C for 2 min and placed in an SU-8 developer 
for 30 seconds to remove the uncrosslinked photoresist. Next, it is rinsed with 2-propanol and dried 
with nitrogen. Finally, a hard bake is performed at 200°C for two hours. The height (15 μm) and 
width (40 μm) of the raised structure on the surface of the fabricated silicon master was measured 
using an Alpha Step-200 surface profiler.  A mixture of PDMS/curing agent (10:1) is poured over 
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the silicon master and then cured at a temperature of 70°C for 4 hours. The PDMS channels are 
then peeled from the silicon master, and reservoir holes were punched into the PDMS by using a 
biopsy punch (Harris Uni-Core, Ted Pella, Inc., Redding, CA). Finally, the PDMS layer was placed 
over a glass plate. This silicon master can be used to produce a large number of PDMS chips.  
   
5.2.2.5 Fabrication of glass microchip electrophoresis: 
The fabrication of glass microchips was accomplished  using standard photolithography 
and wet chemical etching methods.  Our group20, 23 previously described the fabrication method of 
glass/glass microchip. Briefly, a photomask with the microchip design was placed over a 1.8 µm 
thick positive photoresist (AZ1518), chrome coated 4″ × 4″ borosilicate substrate (Telic Company, 
Valencia, CA). The substrate was then exposed to UV light using a UV flood source (ABM Inc., 
Scotts Valley, CA) for 4 seconds. The UV exposed photoresist was then removed by placing the 
glass substrate into AZ300® MIF developer (Capitol Scientific, Inc., Austin, TX) for 20 seconds. 
The glass plate was washed with H2O, dried with nitrogen gas and placed on a programmable 
hotplate (Thermo Scientific, Waltham, MA) and baked at 100 °C for 10 min. The Cr layer was 
then removed using a Cr etchant solution, CR-7S (OM Group. Fremont, Ca) to reveal the 
underlying glass. The exposed glass was etched using a glass etchant solution composed of 
HF/HNO3/H2O (20:40:40) to a depth of approximately 15 µm (note: extreme caution must be taken 
when handling solutions containing HF). Once the desired depth of the trench was reached, the 
plate was washed with a CaCO3 suspension and then water.  
The depth of the trench was measured using Alpha-step 200 profilometer (KLA-Tencor, 
Milpitas, CA). Reservoir holes (0.5 cm diameter) were drilled into the glass plate using a 
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MicroLux® Drill Presse (Berkeley Heights, NJ). A glass coverplate and the newly etched glass 
plate were both rinsed with a calcium assisted bonding solution containing (0.5% Alconox® and 
0.5% calcium acetate)24 and then sealed together under running D.I H2O. The two plates were held 
together using binder clips, and placed into a low-temperature oven at 70 ℃ for 2 hours. At that 
time, the chip was inspected for the absence of Newton rings, and then the temperature was 
increased to 115 °C for 3 hours. The binder clips were then removed, and the glass microchip is 
placed in Isotemp® programmable furnace (Fisher Scientific, Fair Lawn, NJ), and weights were 
placed over the sealed glass plates. The following temperature program was used to thermally 
bond the glass plates: the temperature program began by an initial temperature of 25 °C then the 
temperature was ramped up to 590 °C a rate of 3 °C/min, then to 630°C at a rate of 3.5 °C/min and 
held at 630°C for 10 hours. The temperature was then lowered to 590 °C at a rate of 2.5 °C/min, 
followed by 565 °C at a rate of 1.5 °C/min and held at 565 °C for 30 minutes, this was followed 
by the lowering of the furnace temperature to 505 °C at a rate of 0.5 °C/min, and finally the 
temperature was ramped down to 25 °C at a rate of 5 °C/min. 
  
5.2.2.6 Equipment and microchip operation 
Fluorescence detection was accomplished using a Nikon Eclipse Ti-U inverted microscope 
(Nikon, Melville, NY) coupled with either a 445-nm laser PhoxX diode laser (Market Tech, Scotts 
Valley, CA) or 488-nm diode laser (Spectra-Physics, Irvine, CA) for excitation and a 
photomultiplier (Hammatsu Corporation, Bridgewater, NJ) as the excitation source. The signal 
was amplified using a SR570 low noise current preamplifier at 2 μA/V (Stanford Research 
Systems, Sunnyvale, CA). 
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The applied high voltage was supplied to buffer (B) and sample reservoirs (S) by a 15-kV 
high voltage power supply (Ultravolt, Ronkonkoma, NY), with the sample waste (SW) and buffer 
waste (BW) reservoirs kept at ground. The samples were injected by the gated injected method, 
that was described in previously in chapter 3. An in-house written LabVIEW program was used 
for both control of the high voltage power supply and data acquisition [Figure 2]. 
  
 
Figure 2: Diagram of the capillary microchip LIF system.  
 
5.3 Results and discussion 
5.3.1 Separation of CBI-dynorphin fragments using a pDDA-coated capillary coupled to LIF  
Peptide mixtures of NDA-derivatized Leu-ENK, Dyn A (1-6), Dyn A (1-7) and Dyn A (1-
8) were injected into the modified pDDA coated capillary via pressure injection and the separation 
voltage was applied. In the case of this modified capillary, the positively charged polymer adsorbs 
onto the wall of the negatively charged fused silica capillary. This  causes electrostatic repulsion 
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between the adsorbed polymer and the cationic peptides. The order of migration was Leu-ENK, 
followed by Dyn A (1–6), Dyn A (1–8), and finally Dyn A (1–7). The BGE consisted of 20–80 
mM phosphate buffer (pH 6.8) containing 0.02% v/v pDDA. The separation voltage was –20 kV 
(reverse polarity). The effect of phosphate buffer concentration on the resolution of the four peaks 
is shown in figure 3.  
 
 
Figure 3: Migration times of the four peptides at BGE concentrations 20, 40 60 and 80 mM 
phosphate buffer containing 0.02% pDDA. pDDA-modified capillary. HV= –266 




The separation efficiencies for the dynorphin peaks were calculated for different 
concentrations of phosphate [Figure 4]. The number of theoretical plates (N) was calculated by the 
following equation: 
N = 5.54 (t / W0.5)
2 
where (t) is the time in seconds and (W0.5) is width at half the peak height. The increase in BGE 
phosphate concentration from 20 mM to 60 mM increased the number of theoretical plates from 
approximately 110,000 to 140,000 and 195,000 to 20,000 N for CBI-Dyn A (1-8) and CBI-Dyn 
A(1-7) respectively. However, at 80 mM phosphate, a noticeable decrease in peak efficiency for 
both Dyn A (1-8) and Dyn A (1-7) was observed. That is most likely due to the effect of Joule 







Figure 4: Number of theoretical plates (N) the four CBI-peptides at BGE concentrations 20, 40 
60 and 80 mM phosphate buffer containing 0.02% pDDA using pDDA-modified 
capillary. HV= –266 V/cm, LT= 75 cm, LD = 60 cm, i.d.= 50 µm. 
 
The optimum BGE was found to be composed of a phosphate buffer at a concentration of 
40 mM containing 0.02% pDDA. . The electropherogram obtained for the separation of the four 




Figure 5: Separation of (1) CBI-Leu-ENK, (2) CBI-Dyn A (1–6), (3) CBI-Dyn A (1–8), (4) CBI-
Dyn A (1–7). pDDA-modified capillary. HV= –20 kV, LT= 75 cm, LD = 60 cm i.d.= 
50 µm; BGE: 40 mM phosphate buffer solution (pH 6.8) containing 0.02% pDDA. 
 
 
A major goal of this project was to develop a microchip electrophoresis system that can  
detect dynorphin and its metabolites at endogenous concentrations by using a sensitive detection 
method, such as LIF.  This method could then be further developed to be used as an on-line 
derivatization and analysis system for detection of dynorphin in brain microdialysis samples. 





5.3.2 Development of a microchip electrophoresis system for the separation of dynorphins 
As was previously mentioned, ME is a fast separation technique, which has the abilities to 
for performing multiple sequential injections. ME also has the potential to incorporate continuous 
sampling by coupling to MD with on chip derivatization. Thus, the development of ME system 
that can offer continuous sampling, with on-chip derivatization, separation and LIF detection of 
abnormal levels of dynorphins would be useful for monitoring and the study the effect of these 
opioid peptides has on neurological disorders.  
 
5.3.2.1 PDMS/ glass hybrid microchip electrophoresis of FITC derivatized dynorphins 
 FITC was initially was chosen as the derivatizing agent for the ME-LIF analysis of the 
dynorphins fragments due to its excellent fluorescence quantum yield ( > 0.85) and its 
compatibility with the 488 nm Argon ion laser. In order to perform an electrophoretic separation 
on a microchip, a stable electroosmotic flow (EOF) is required for both sample injection and to 
move all analytes to the detector. Materials such as PDMS do not have a strong surface charge. 
Thus surfactants, such as SDS, are frequently used to provide a charge to the channel walls. The 
addition of SDS provides a negatively charged layer by hydrophobic interaction of the surfactant 
hydrophobic tail to the wall of the PDMS26 microchip. ME analysis of FITC derivatized Dyn A 
(1-8), Dyn A(1-13), Dyn A(1-17) was first performed [Figure 6A, 6B and Figure 7 respectively] 
using a BGE comprising of 15 mM sodium phosphate (pH 7),  2 mM SDS and 5% DMSO. The 
applied voltages to the buffer and sample reservoir was 2,400 V and 2,200 V respectively. The 
peptide samples were injected using a 1 s gated injection method.  
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Molecules derivatized with FITC typically produce derivatives with strong fluorescent 
intensity. However, the disadvantages of the use of FITC for dynorphins derivatization included 
the long reaction time that was required. In addition, the reagent also produced a high-intensity 
fluorescent signal, that hindered the separation of dynorphin peptides derivatized with FITC 






























Figure 6: PDMS/glass ME of FITC labeled dynorphins. A: 20 µM FITC-Dyn A 1-8 (1), FITC (2). 
B: electropherogram of 20 µM FITC-Dyn A1-13 (1), FITC (2). Separation channel 
length 5 cm. HV (B/S): 2400/ 2200 V. BGE: 15 mM sodium phosphate (pH7) with 2mM 





Figure 7: Electropherogram of 20 µM FITC-Dyn A 1-17 (1), FITC (2). The PDMS/ glass 
microchip used with a 5-cm separation channel, HV: 2,400 V (B), 2,200 V (S), 1-sec 






Figure 8: Electropherogram of a mixture of FITC labeled Dyn A (1-8), FITC-Dyn A (1-13) and 
FITC-Dyn A (1-17). PDMS/ glass microchip used with a 5-cm separation channel, HV: 
2,400 V (B), 2,200 V (S), 1-sec gated injection. BGE: 15 mM sodium phosphate (pH7) 
with 2mM SDS and 5% DMSO. Excess FITC comigrated with all three labeled 
peptides. *Shows degradation product of FITC peak. 
  
5.3.2.2 Glass/ glass microchip electrophoresis of NDA/CN derivatized dynorphins 
The composition of the BGE is known affect the migration time, resolution of analytes, 
and the amount of current within the ME channels. The initial separation of the two NDA/CN 
derivatized peptides Leu-ENK and Dyn A (1-8) was performed by using a 15 cm long serpentine 
glass/glass microchip with an applied voltage of  8,500 V (B) and 7,500 V (S) that corresponds to 
a field strength of ~ 430 V/cm (calculated using Kirchoff’s Laws).  A 1 s gated injection was used. 
The BGE constituted of 15 mM boric acid (pH 10) containing 10% methanol. The electrolyte 
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within BGE and reaction mixture was changed from sodium phosphate to boric acid because boric 
acid is less conductive and thus produced lower current than BGE containing sodium phosphate. 
Attempts to use phosphate as BGE was found to cause excessively high currents.  
Figure 9 shows the electropherogram of a mixture of the two peptides CBI-Dyn A (1-8) 
and CBI-Leu-ENK. The peak of CBI-Dyn A (1-8) exhibited some tailing and a lower peak height 
than was expected (LOD ≈ 5 µM). An attempt was then performed to improve peak height and 
reduce peak tailing of CBI-Dyn A (1-8) by the addition of Brij-35 as an additive to the BGE (0.02 
and 0.06 mM). Brij®-35 is a nonionic surfactant (critical micelle concentration 0.09 mM) that has 
been shown to decrease absorption of cationic peptides to microchip glass channels. Unfortunately, 


















Figure 9: Electropherogram of ME injection of a mixture of (1) 25 µM Dyn A (1-8) and (2) 25 
µM Leu-ENK on a 15 cm serpentine glass/glass microchip. BGE: 15 mM boric acid 










Figure 10: The ME electropherogram of a mixture of (1) 25 µM Dyn A (1-8) and (2) 25 µM 
Leu-ENK on a 15-cm serpentine glass/glass microchip. BGE: 15 mM boric acid (pH 




For the analysis of the fluorescent derivatized peptide CBI-Dyn A (1-17), both the sample 
reaction mixture and BGE composition and pH were adjusted to contain a higher concentration of 
an organic solvent.  In addition, the pH was increased to pH 10. The addition of DMSO was found 
to improve the solubility of CBI-Dyn A(1-17), where the absence of DMSO in the BGE lead to 
the disappearance of the  peak. Increasing the pH of the reaction mixture to pH 10 increased the 
rate of the reaction of the amine on Lys (approximately 4 mins) compared to that of the N-terminal 
of Dyn A (1-17). The selective derivatization of peptides with more than one primary amine has 
been previously described by our group and others for ϵ-amino group of the Lys residue for opioid 
peptide substance P (1-11) and some of its fragments with NDA/CN. Figure 11 shows a microchip 
electropherogram if an injection of 25 µM of CBI-Dyn A (1-17) on a 15-cm glass microchip, with 








Figure 11: Microchip electropherograms of a gated injection of 25 µM Dyn A (1-17) derivatized 
with NDA/CN. HV: 8,500 V (B), 7,500 V (S), 1-second gated injection. BGE: 5 mM 
boric acid (pH 10) containing 15% DMSO.  
  
5.4 Conclusions and Future Directions 
For the development of a microchip system with continuous sampling and analysis of 
dynorphins, the selection of fluorescent derivatization method is vital. The use of the fluorogenic 
agent NDA/CN for the fluorescent derivatization of dynorphin was found to be a preferred 
derivatizing method compared to FITC. The use of FITC as a derivatizing agent for microchip 
electrophoresis of dynorphin will require additional steps of sample preparation to remove excess 
FITC dye from the sample prior to analysis. This can be accomplished using as solid-phase 
extraction (SPE) or size exclusion chromatography before the introduction of the peptide sample 
into the microchip. For MD samples this would mean that the sample would need to be derivatized 
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pre-column over several hours, and then an additional step of removing any excess FITC would 
be needed since excess FITC has shown to interfere with ME analysis of these peptides. Thus the 
use of NDA/CN is a more favorable fluorescent derivatizing method for the application. However, 
the difference in reaction rates between various fragments of dynorphin and the fluorogenic agent 
may require future adaptation in the microchip design, for example, valves to split the sample to 
react at different reaction conditions, or the incorporation of mixing channels to increase the 
reaction rates.   
159 
 
5.5 Reference  
1. Na, D. H.; Lee, K. C., Capillary Separation Techniques. In Handbook of Pharmaceutical 
Biotechnology, John Wiley & Sons, Inc.: 2006; pp 469-510. 
2. Laing, T. D.; Marenco, A. J.; Moore, D. M.; Moore, G. J.; Mah, D. C. W.; Lee, W. E., 
Capillary electrophoresis laser-induced fluorescence for screening combinatorial peptide 
libraries in assays of botulinum neurotoxin A. J. Chromatogr. B 2006, 843 (2), 240-246. 
3. Verpillot, R.; Esselmann, H.; Mohamadi, M. R.; Klafki, H.; Poirier, F.; Lehnert, S.; Otto, 
M.; Wiltfang, J.; Jean-Louis, V.; Taverna, M., Analysis of amyloid-beta peptides in 
cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection. 
Anal. Chem. 2011, 83 (5), 1696-703. 
4. Ban, E.; Song, E. J., Recent developments and applications of capillary electrophoresis 
with laser-induced fluorescence detection in biological samples. J. Chromatogr. B Analyt. 
Technol. Biomed. Life Sci. 2013, 929, 180-6. 
5. Banks, P. R., Fluorescent derivatization for low concentration protein analysis by 
capillary electrophoresis. TrAC, Trends Anal. Chem. 1998, 17 (10), 612-622. 
6. De Antonis, K. M.; Brown, P. R., Analysis of derivatized peptides using high-
performance liquid chromatography and capillary electrophoresis. Adv. Chromatogr. 
1997, 37, 425-52. 
7. García-Campaña, A. M.; Taverna, M.; Fabre, H., LIF detection of peptides and proteins 
in CE. Electrophoresis 2007, 28 (1-2), 208-232. 
8. Kostel, K. L.; Lunte, S. M., Evaluation of capillary electrophoresis with post-column 
derivatization and laser-induced fluorescence detection for the determination of substance 
P and its metabolites. Journal of Chromatography B: Biomedical Sciences and 
Applications 1997, 695 (1), 27-38. 
9. Banks, P. R.; Paquette, D. M., Monitoring of a conjugation reaction between fluorescein 
isothiocyanate and myoglobin by capillary zone electrophoresis. J. Chromatogr. 1995, 
693 (1), 145-154. 




11. Soper, S. A.; Chamberlin, S.; Johnson, C. K.; Kuwana, T., The Intramolecular Loss of 
Fluorescence by Lysine Derivatized with Naphthalenedialdehyde. Appl. Spectrosc. 1990, 
44 (5), 858-863. 
12. Zotou, A.; Notou, M., Study of the naphthalene-2,3-dicarboxaldehyde pre-column 
derivatization of biogenic mono- and diamines in mixture and fluorescence-HPLC 
determination. Anal. Bioanal. Chem. 2012, 403 (4), 1039-48. 
13. De Montigny, P.; Riley, C. M.; Sternson, L. A.; Stobaugh, J. F., Fluorogenic 
derivatization of peptides with naphthalene-2,3-dicarboxaldehyde/cyanide: Optimization 
of yield and application in the determination of leucine-enkephalin spiked human plasma 
samples. J. Pharm. Biomed. Anal. 1990, 8 (5), 419-429. 
14. Lunte, S. M.; Mohabbat, T.; Wong, O. S.; Kuwana, T., Determination of desmosine, 
isodesmosine, and other amino acids by liquid chromatography with electrochemical 
detection following precolumn derivatization with naphthalenedialdehyde/cyanide. Anal. 
Biochem. 1989, 178 (1), 202-7. 
15. De Montigny, P.; Stobaugh, J. F.; Givens, R. S.; Carlson, R. G.; Srinivasachar, K.; 
Sternson, L. A.; Higuchi, T., Naphthalene-2,3-dicarboxyaldehyde/cyanide ion: a 
rationally designed fluorogenic reagent for primary amines. Anal. Chem. 1987, 59 (8), 
1096-1101. 
16. Lacroix, M.; Garrigues, J.-C.; Couderc, F., Reaction of Naphthalene-2,3-
Dicarboxaldehyde with Enkephalins for LC-Fluorescence and LC-MS Analysis: 
Conformational Studies by Molecular Modeling and H/D Exchange Mass Spectrometry. 
J. Am. Soc. Mass Spectrom. 2007, 18 (9), 1706-1713. 
17. Little, M. J.; Paquette, D. M.; Harvey, M. D.; Banks, P. R., Single-label fluorescent 
derivatization of peptides. Anal. Chim. Acta 1997, 339 (3), 279-288. 
18. Yang, W.-c.; Yeung, E. S.; Schmerr, M. J., Detection of prion protein using a capillary 
electrophoresis-based competitive immunoassay with laser-induced fluorescence 
detection and cyclodextrin-aided separation. Electrophoresis 2005, 26 (9), 1751-1759. 
19. Mahmoudian, J.; Hadavi, R.; Jeddi-Tehrani, M.; Mahmoudi, A. R.; Bayat, A. A.; Shaban, 
E.; Vafakhah, M.; Darzi, M.; Tarahomi, M.; Ghods, R., Comparison of the 
Photobleaching and Photostability Traits of Alexa Fluor 568- and Fluorescein 
Isothiocyanate- conjugated Antibody. Cell Journal (Yakhteh) 2011, 13 (3), 169-172. 
161 
 
20. Huynh, B. H.; Fogarty, B. A.; Martin, R. S.; Lunte, S. M., On-Line Coupling of 
Microdialysis Sampling with Microchip-Based Capillary Electrophoresis. Anal. Chem. 
2004, 76 (21), 6440-6447. 
21. Huynh, B. H.; Fogarty, B. A.; Nandi, P.; Lunte, S. M., A microchip electrophoresis 
device with on-line microdialysis sampling and on-chip sample derivatization by 
naphthalene 2,3-dicarboxaldehyde/2-mercaptoethanol for amino acid and peptide 
analysis. J. Pharm. Biomed. Anal. 2006, 42 (5), 529-534. 
22. Meneses, D.; Gunasekara, D. B.; Pichetsurnthorn, P.; da Silva, J. A. F.; de Abreu, F. C.; 
Lunte, S. M., Evaluation of in-channel amperometric detection using a dual-channel 
microchip electrophoresis device and a two-electrode potentiostat for reverse polarity 
separations. Electrophoresis 2015, 36 (3), 441-448. 
23. Oborny, N. J.; Costa, E. E. M.; Suntornsuk, L.; Abreu, F. C.; Lunte, S. M., Evaluation of 
a Portable Microchip Electrophoresis Fluorescence Detection System for the Analysis of 
Amino Acid Neurotransmitters in Brain Dialysis Samples. Analytical sciences : the 
international journal of the Japan Society for Analytical Chemistry 2016, 32 (1), 35-40. 
24. Allen, P. B.; Chiu, D. T., Calcium-Assisted Glass-to-Glass Bonding for Fabrication of 
Glass Microfluidic Devices. Anal. Chem. 2008, 80 (18), 7153-7157. 
25. Tang, G. Y.; Yang, C.; Gong, H. Q.; Chai, J. C.; Lam, Y. C., Numerical simulation of 
Joule heating effect on sample band transport in capillary electrophoresis. Anal. Chim. 
Acta 2006, 561 (1), 138-149. 
26. Guan, Q.; Noblitt, S. D.; Henry, C. S., Electrophoretic separations in 
poly(dimethylsiloxane) microchips using a mixture of ionic and zwitterionic surfactants. 
























 6.1 Conclusions 
 This dissertation shows the development of electrophoresis methods for the analysis of the 
opioid peptide dynorphin A (1-17) and its metabolites. Dynorphins (Dyn) are neuropeptides that 
have one or more basic amino residues such as Lys and Arg in their chemical structure, in addition 
to an ionizable nitrogen atom at the peptides N-terminal1. 
 One of the research objectives focused on the development of an analytical method towards 
a capillary electrochromatography (CEC) separation method of dynorphins. CEC with UV 
detection (214 nm) was used to separate and detect several metabolites of Dyn A (1-17). Fused-
silica capillaries were coated with gold nanoparticles stabilized with a positvily chagred polymer 
polydiallyldimethylammonium chloride (pDDA-GNPs). These capillary coated polycationic  
nanoparticals were used to minimize the undesirable adsorption of the positively charged 
dynorphin peptides to the surface of negatively charged fused-silica capillaries. PDDA-GNPs 
coated capillaries were also compared to pDDA coated capillaries on the resolution of separation. 
The pDDA-GNPs coated capillary was able to separate a peptide mixure of dynorphins fragments 
with the advantage of providing a 20% greater anodal EOF (EOF = −6.3 × 10-4 cm2/V.s) compred 
to pDDA (alone) coated capillary (EOF = −5.2 × 10-4 cm2/V.s) The GNPs coated capillaries were 
then used for the separation of Dyn A (1-17) and seven of its key metabolites, Dyn A (2-17), Dyn 
A (1-13), Dyn A (1-11), Dyn A (1-8), Dyn A (1-7), Dyn A (1-6) and Leu-enkephalin (Leu-ENK). 
Evaluated parameters for the separation of fragments of Dyn A included the effect of the capillary 
length, changes in the separation voltage and the adjustment of the ionic strength of the background 
electrolyte (BGE). The best separation of all eight peptides was found to be 40 mM sodium acetate 
buffer (pH 5) containing 5% GNP, and a field strength of −306 Vcm-1. This method was used for 
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the separation of peptide mixtures of Dyn fragments arising from tryptic digestion Dyn A (1-17) 
over a nine-hour study.  
 Capillary coating with positively charged materials was found to mask the electrostatic 
adsorption of dynorphins to the negatively charged capillary surface. However, to achieve the 
limits of detection necessary for the detection of Dyn metabolites in a biological sample, laser 
induced fluorescence (LIF) was used. Because dynorphins are not intrinsically fluorescence when 
excited by a 442 nm laser, four fragments of Dyn A were derivatized with the fluorogenic agent 
naphthalene-2,3-dicarboxaldehyde (NDA) in the presence of sodium cyanide (CN) and produced 
a fluorescent 1-cyanobenzoic[f]isoindole derivatives. The fluorescent CBI derivatives were 
separated using a pDDA coated capillary (LT: 75 cm, LD:60 cm), phosphate buffer (pH 6.8) as the 
BGE, and operated under reverse polarity (applied voltage: −20 kV), and then detected by an 
external LIF detector (λex: 442nm, λem: 490nm). The effect fo BGE ionic strength on migration 
time and efficiency of each of the separated peptides was investigated.  
 Finally, efforts were made to develop a microchip electrophoresis (ME)-LIF system for the 
separation of dynorphin, for the ultimate goal is developing an on-line microdialysis(MD)-ME-
LIF for measuring levels of dynorphins in vivo. For ME analysis, two type of microchips were 
fabricated. The first was polydimethylsiloxane (PDMS)/glass microchip and the second was 
borosilicate glass microchip. The opioid peptides were derivatized with either fluorescein 
isothiocyanate (FITC) and excited using 488 nm laser or derivatized with NDA/CN excited using 
445 nm laser. The use of NDA/CN for the fluorescent derivatization of Dyn was found to be a 
more favorable choice compared to FITC. When excess of the fluorescent agent FITC is added to 
the dervtization mixture, unreacted FITC was found to interfered with separation. Also, the 
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derivatization of peptides with FITC requires several hours, which may not be ideal for the 
development of an on-line sampling system to obtain high temporal resolution. 
  
6.2 Future directions 
6.2.1 Future directions in the development of a MD-ME-LIF method for the study of 
dynorphins 
 Concerning the MD-ME-LIF system for the analysis of dynorphins in MD samples, 
changes in the BGE, materials used for microchip fabrication or the modifications microchip 
design could potentially improve separation. Our group as previously developed an on-chip 
derivatization microchip that was used for amino acid analysis [Figure 1]2-4. In addition, a search 
for a newer fluorescent derivatization agent such as o-phthalaldehyde/ SAMSA fluorescein may 
improve LODs5. 
  
6.2.2 Development of an analytical method for the investigation of the metabolism of 
dynorphin A using CEC coupled to mass spectrometry 
 UV detection systems are the most used detection systems in both CE and CEC commercial 
systems. However, for peptide analysis using CE with UV detection, UV is restricted by its poor 
limits of detection. LIF detection is a more sensitive detection method that can also be found to be 
coupled to CE systems. However, peptide detection using LIF may require derivatization with a 
fluorescent tag. The advantage of the use of mass spectrometry (MS) in CE and CEC analysis is 
MS is a known to be a sensitive detection method, which can provide structural information of the 
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detected peptides. As mentioned previously, Dynorphins are peptides that have high pIs, making 
them difficult to analysis using CE. In our lab efforts are being made towards the development of 
CEC capillaries that are coated with the multicharged pDDA polymer and pDDA-GNPs. The 
coated capillary would then be connected to the electrospray ionization (ESI) interface of a Thermo 
Fisher LTQ XL® Linear Ion Trap Mass Spectrometer. 
 
 
Figure 1: Design of on-chip derivatization microchip for amino acid analysis2 
   
6.2.3 The development of glass microfluidic device coupled to ESI-MS for neuropeptides 
involved in pain signaling pathways 
 Several endogenous neuropeptides are relased in response to pain stimulation6, among 
these neuropeptides are dynorphin A, substance P7 and β-endorphin8 [Table 1]. Studies of the 
relationship between these neuropeptides under pain stimuli or chronic pain have been reported, 
for example in the peripheral nervous system β-endorphin is known to inhibit the release substance 
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P a peptide that is associated with transmission pain9. A microfluidic chip “pain chip” can be 
fabricated in which microfluidic chip performed as the electrospray source. Ramsey’s10-11 group 
have reported the development of a ME-ESI-MS system for protein and peptide separation. The 
use of MS as the selective detection method can offer structural information of the analyte. In 
addition, it does not require the additional derivatization step that may be necessary for analytes 
that are not natively fluorescent for LIF detection. Furthermore, fluorescent tagging may 
complicate the development of a separation method, due to the changes in charge/size ratio of 
analytes after tagging. Similar to ME-ESI-MS microchip that was developed by Ramsey’s group 
[Figure 2], a borosilicate chip would be fabricated to include a 300 µm thick electrospray tip and 
a single corner of a rectangular glass chip, which forms the ESI interface.  
 
Peptide  Structure 
Dynorphin A  YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE 
Substance P  RPKPQQFFGLM 
β-endorphin YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE 
 











Figure 2: Schematic of the CE-ESI-MS chips (A) short-channel (B) long-channel (C) image of 
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A.1.1 The blood-brain barrier and its function 
The blood-brain barrier (BBB) is composed of brain endothelial cells that form the vascular 
endothelial capillary wall1 of the BBB. The supporting structure of the BBB includes astrocytes, 
pericytes, and the basement membrane [Figure 1]2-4. The main functions of the BBB are to regulate 
the entry of ions, macromolecules, and nutrients that are required by the CNS and protect the 
nervous tissues from neurotoxins5. The BBB acts as a physical barrier due to the presence of tight 
junctions (TJ) between endothelial cells that reduces the influx of harmful substances into the 
brain. It also acts as a metabolic barrier6 due to the present various metabolic enzymes such as 
aminopeptidase A, aminopeptidase M, glutamyl aminopeptidase, endopeptidase7 and cytochrome 
P-4508 at the BBB. The transport of nutrients, cells components, and toxins across the BBB is 
affected by the physiological and pathological states9-10 of the organism. 
 
 
Figure 1: Structure of the blood brain barrier.10 (Reprinted with permission) 
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A.1.1.1 Transport across the BBB 
The pathway that a molecule takes to cross the BBB is based on the molecule’s charge, 
size, the degree of lipophilicity or availability of specific carriers at the luminal of the BBB for the 
substance. There are five basic mechanisms for the transport of molecules across the BBB. These 
are paracellular diffusion, transmembrane diffusion, adsorptive mediated endocytosis, receptor-
mediated endocytosis and a carrier-mediated transport [Figure 2].  
   
A.1.1.1.1 Paracellular diffusion  
A very limited number of molecules may be transported to the brain via the paracellular 
pathway. Small polar molecules, such as ethanol and mannitol, can pass from the blood into the 
brain through openings in the TJ of the BBB endothelial cells11. The opening of the TJ is highly 
regulated by constituent proteins including occludin, claudin-5, junctional adhesion molecules, 
and cadherins12. An irregular increase in paracellular diffusion can occur due to diseases such as 
multiple sclerosis13, HIV14, and cancer15. In addition, the administration of drugs, such as 
hyperosmotic mannitol, can cause shrinkag of the endothelial cell of the BBB and opening of the 
TJ, that can lead to the entry of molecules into the brain by the paracellular diffusion pathway that 
would normally be restricted16. 
 
A.1.1.1.2 Transmembrane passive diffusion 
Small molecular weight lipid soluble molecules are generally able to cross the BBB by 
transmembrane passive diffusion. Factors that can restrict molecules from being transported across 
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the BBB via transmembrane passive diffusion include, low lipophilicity, size (larger than 400-500 
Da) 10, 17, affinity to plasma proteins (high-affinity plasma proteins can reduce BBB 
permeability)18, and the number of hydrogen bonds (H-Bonds) that the molecule can form (the 
formation of more than eight H-bonds increases the free energy requirements to transfer from the 
polar phase to the nonpolar phase)10, 19. Examples of compounds that can passively diffuse across 
the membrane of endothelial cells of the brain are CNS drugs including fluoxetine and sertraline. 
 
A.1.1.1.3 Adsorptive mediated endocytosis 
This is a nonspecific mechanism of transport of molecules across the BBB. Due to the 
anionic nature of the cerebral endothelial cells, cationic molecules are first electrostatically 
adsorbed onto the cell's membrane and then undergoes endocytosis through the formation of 
vesicles20 and are transported into the cell. Examples of molecules that are transported by this 
mechanism include arginine-containing peptides and polycationic proteins such as β-endorphin-
cationized albumin complex21. 
 
 
A.1.1.1.4 Receptor-mediated endocytosis 
 Specific receptors within the brain endothelial cells can bind to ligands in the blood side 
and form a receptor-ligand complex7. This is then followed by to the formation of transport 
vesicles, and the complex is transported across the cell to the brain, where the ligand is then 
released. An example of compounds that are carried by this method includes peptides and proteins 




A.1.1.1.5 Carrier-mediated transport 
  Essential polar molecules such as glucose24, vitamins25, amino acid26, and certain peptides 
are all examples of ligands that are carried by structural specific carrier-mediated transporters from 
the blood to the brain11. GLUT-127, and (PTS)-428 are examples of carrier transporters for glucose 
and luteinizing hormone-releasing hormone respectively. Some of these specific transport systems, 
such as glucose or amino acid transporters, have been explored to improve drug design and 
enhance permeability across the BBB for poor CNS permeability drugs.21  
   
 
 





A.1.1.1.6 Methods used to study the transport of substances across the BBB  
 Various in vitro and in vivo experimental methods have been reported for the study of the 
transport of substances across the BBB and to investigate the effect of these substances on the 
integrity of the BBB. Examples of the application of these techniques include the study of the 
disturbance to BBB due to neurological diseases such as Alzheimer’s disease and the investigation 
of CNS drugs transport mechanisms at the BBB.  
 
A.1.1.1.6.1 In vitro methods for the study of the BBB 
 Some of the advantages of using in vitro models to study the BBB are that many of the 
physical characteristics and cell biological processes of the BBB, such as the presence of low 
pinocytic activity, and low fenestrations and presence of efflux carriers such as p-glycoprotein30 
can be found in this model. These similarities make the in vitro models of the BBB a convenient 
technique to be used as a first-pass compound screening method11. Several cell lines have been 
reported as in vitro models of the BBB. These include microvessels endothelial cells isolated from 
porcine31, bovine30 or human autopsy brains32. In addition,  other cell lines, such as epithelial cells 
from Madin–Darby canine kidney epithelial cells33 and BBB models generated from human 
pluripotent stem cells have been used31. Although these in vitro models are useful for probing the 
BBB, they have limitations including the isolation of the brain microvesicle cells, which can be 
challenging and labor-intensive and exhibit poor viability34. In addition, these in vitro models may 
not completely represent in vivo conditions due to the difference in the barrier tightness and 




A.1.1.1.6.2 In vivo and in situ methods for the study of the BBB 
The intravenous injection (IV) method can be considered as the “gold standard” for BBB 
brain uptake studies35 because the physiological conditions of the test animal are intact. This 
approach can provide the most accurate picture of the state and amount of a substance that is 
transported to the brain32, 35. Substances are administered by IV to the animal model and samples 
can be collected from plasma, cerebrospinal fluid (CSF) or the brain and at different time points. 
A limitation of the IV method is that, in most cases, it does not provide information about the 
specific activity of ions, hormones, peptides, and proteins on the transport of the studied substances 
at the BBB. This requires the performance of multiple studies with a large number of test animals.  
In addition, a large number of test animals may also be required to provide statistical significance 
due to the larger animal-to-animal variability that is mostly seen with animal models.  
The in situ perfusion method is similar to the IV method for the investigating BBB 
permeability, where the in situ method uses the same in vivo structure of the BBB. However, in 
this method. the circulating blood of the animal is substituted with a solution that contains the 
study compounds dissolved within a perfusion solution. The solution’s composition can also be 
modified and delivered directly to the brain35-36. The use of an in situ model also has the advantage 
of that both the studied substance and perfusion solution can be delivered to the brain at levels that 
are usually not tolerable in vivo35. In addition, the in situ perfusion method can eliminate the effect 
of metabolism by the liver or other organs of the studied compounds, and thus an intact compound 
can reach the BBB without any change in its structure due to first pass metabolism by the liver32, 
35. However, a limitation of this method includes that it is harder to perform than IV methods32. 
Also, analogous to IV methods, a large number of animals may be required for in situ perfusion 




A.1.1.2 Dysfunction of the BBB in disease 
Several diseases have been reported to cause the dysfunction of the BBB. This can be due 
to downregulation of the transport of specific molecules such as glucose (Alzheimer disease)10,  
reduction of the activity of P-glycoproteins in the endothelial cells at the BBB (Parkinson’s 
disease)37, or the disruption of the BBB tight junctions (HIV)38-39 or breakdown of the BBB 
(multiple sclerosis)38.  
 Various markers have been used to study the integrity of the BBB in both in vivo and in 
vitro models. Examples of these markers used include Evans blue40, sodium fluorescein41, 
fluorescein-labeled dextran and radiolabeled markers (sucrose, inulin or mannitol)42. The 
characteristics of an ideal marker should include that the molecule is non-toxic, metabolically 
stable, non-binding to tissue or plasma proteins, and easily quantifiable43.  
 
A.1.2 Dynorphin A(1-6) effect in the BBMEC monolayer permeability 
The study of the metabolism of dynorphin A (Dyn) by enzymes in both blood and tissues 
of the CNS has been reported by several research groups (see Chapter 2). Our group previously 
studied the transport of the peptide Dyn A(1-6) across a monolayer of bovine brain microvascular 
endothelial cells (BBMEC) as an in vitro model of the BBB44. The effect of preincubation of the 
cells with Dyn A(1-6) on the permeability of fluorescein was also studied. Fluorescein was used 
as a low molecular weight permeability marker to monitor the integrity of a monolayer of BBMEC. 
Isolated microvascular endothelial cells from gray matter of bovine brain were grown on a 
polycarbonate membrane and placed in a Side-by-Side® diffusion chamber [Figure 3]. For 
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transport studies of Dyn A(1-6), the peptide was added at the donor side, and at different time 
points, aliquots were taken from the receiver side. Once the transport studies were completed, 
fluorescein was added to the donor side, and aliquots were collected from the receiver side at 
different time points to assess the permeability of BBMECs. 
In these studies, Dyn A(1-6) was found to permeate at the BBMECs layer in both apical-
to-basolateral and basolateral-to-apical directions (37 ℃). It also showed reduced permeation at a 
low temperature (4 ℃) [Figure 4A] suggesting the transport of the peptide is by a carrier-mediated 
transport system44. Also, preincubation of Dyn A(1-6) with the BBMECs led to an increase of the 
transport of fluorescein across the monolayers (37 ℃) and a  lower level of fluorescein transport 
was observed at the lower temperature (4 ℃) [Figure 4B]. These findings were similar to those 
reported by Thompson et.al. concerning the transport of fluorescein, 14C-sucrose or 3H-mannitol 
across the BBMEC due to the effect of [Leu]-enkephalin (Leu-ENK). They also reported the effect 
of the transport of 14C-sucrose at the BBMEC was lowered by the presence of the opioid receptor 
antagonist naloxone with Leu-ENK, indicating that effect of the peptide may be due to activation 
of opioid receptors (µ or δ)45-46.  
Dyn A(1-6) has an affinity to all three of the known opioid receptors (µ, δ, and κ) and may 
cause the opening of the BBB by activation of these receptors. Dyn A(1-6) YGGFLR shares 
structural similarities to Leu-ENK (YGGFL), Thompson et.al hypothesized that the enhancement 
in the permeability of low molecular weight molecules is possibly due to an alteration of the TJ or 
due to the formation of small pores in the monolayer of BBMEC or both. This may be similar to 
how Dyn A(1-6) causes an enhancement of the permeability of fluorescein seen with the in vitro 
studies of the peptide. It is also possible that Dyn A (1-6) not only affects the permeability of low 
molecular weight molecules at the BBB, but it may also play a role in increasing the permeability 
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of the parent peptide Dyn A(1-17) or other harmful substances into the CNS. These findings lead 
us to further investigate the effect of Dyn A(1-6) on BBB  using Sprague-Dawley® (SD) rats as in 
situ animal model. 
 
 
Figure 3: Side-by-Side® diffusion chamber used for monitoring in-vitro transport across the 






Figure 4: A) Bi-directional apparent permeability coefficients (Papp) of Dyn A(1–6) and the 
temperature dependence of the A-to-B transport of Dyn A(1–6). (B) Effect of 
pretreatment with Dyn A(1–6) on the BBB permeability of fluorescein44. (Reprinted 
with permission) 
  
 A.2 Materials and methods  
A.2.1 Peptide and buffer saline solutions 
Dyn A(1-6) (Shanghai MoCell Biotech; Shanghai, China), or scrambled peptide 
(GLYRFG) (Shanghai MoCell Biotech; Shanghai, China) with DMSO were each dissolved in a 
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bicarbonate buffer physiological saline containing 0.5% v/v tween 20. The bicarbonate-buffer 
physiological saline was prepared with NaCl (142 mmol/L), NaHCO3 (28 mmol/L), KH2PO4 (4.2 
mmol/L), CaSO4 (1.7 mmol/L), MgSO4 (1 mmol/L) and D-glucose (6 mmol/L). The solution was 
filtered through a sterile 0.2 μm cellulose nitrate filter (Nalgene®) and incubated with 5% CO2 in 
95% humidity before the experiment at 37°C. Radiolabeled 14C-mannitol (Moravek Biochemicals 
Inc; Brea, CA) was dissolved within the perfusion bicarbonate-buffered physiological saline 
solution, to be then used as the permeability marker.  
  
A.2.2 In situ rat brain perfusion 
A modification of the in situ brain perfusion technique developed by Y. Takasato36 was 
performed to study the effect of Dyn A(1-6) on the integrity of the BBB. Briefly, the animal 
surgeries were conducted on two groups of male SD rats (weight 250-350 g). All animal 
experiments were carried out in accordance with regulations of the Institutional Animal Care and 
Use Committee (IACUC) at the University of Kansas. Each rat used in the perfusion experiments 
was initially anesthetized by IP administration of 100 mg/kg ketamine and 5 mg/kg xylazine and 
a heat lamp was used to maintain the animals body temperature. This was followed by insertion of 
a cannula into the left common carotid artery (LCCA) with a polyethylene catheter (PE-50) 
containing heparinized saline (100 I.U./mL) and then  following ligation of the external branches 
of the artery using surgical thread. This was then followed by cardiac puncture under anesthesia 
and immediately after was then followed by 20s pre-perfusion with perfusion solutions.  
Rats were perfused with 10 mL of either a perfusion solution (control solution) or peptide 
dissolved in the perfusion solution (peptide solution), which was then followed by perfusion of a 
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solution of 14C-mannitol, followed by a 5 s post-perfusion wash with saline. Finally, while still 
under anesthesia the procedure was terminated by decapitation of the animal and the brain tissue 
was harvested. 
  
A.3 Results and discussion 
A.3.1 Comparison of the effect of dynorphin A 1-6 to control  
The activity of the peptide Dyn A(1-6) regarding the opening of the blood-brain barrier 
was investigated. Two different concentrations of Dyn A (1-6) 0.75 mM (n=3) and 1.0 mM (n= 3) 
were compared to the control (n=5). The results show an effect of the Dyn A(1-6) on the 
permeability of 14C-mannitol compared to the control [Figure 5]. However, there was no 
statistically significant difference between all the groups (p-value > 0.05). This is most likely due 
to the animal-to-animal variability as well as the relatively small sample size (n=3) used for each 
of the peptide groups. 
   
A.3.2 Comparison of the effect of dynorphin A (1-6) to a scrambled peptide on BBB transport 
The effect of the scrambled peptide (GLYRFG) on the permeability of 14C-mannitol at the BBB 
was also investigated. It was hypothesized that this peptide would not open the BBB due to weak 
binding to opioid receptors. A concentration of 0.75 mM of the scrambled peptide perfusion 
solution containing 0.17% v/v DMSO was prepared. DMSO was added due to the perfusion 
solution because of the low solubility of the peptide GLYRFG in the bicarbonate buffer saline 
solution. The control solution was made using the same volume of DMSO added to the perfusion 
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solution. Figure 6 shows a comparison of the effect of the scrambled peptide (n= 3) to its control 
(n= 1) within the same day. The scrambled peptide did not show an increase in permeability of 





Figure 5: Comparison of the effect of the dynorphin A(1-6) on the BBB permeability of 14C- 












Figure 6:  Comparison of the effect of the scrambled peptide (GLYRFG) vs. control on the 




     A.4 Conclusions  
The result of in situ perfusion study indicate that the neuropeptide Dyn A(1-6) has activity 
at the BBB. Although the results of the in situ perfusion study are not statistically significant, there 
is a trend of the effect of the neuropeptide on the BBB. We believe, based on previous in vitro 
experimental results performed by our lab, and the in situ rat experiments carried out on SD rats, 
that the peptide may activate opioid receptors. The activation of opioid receptors leads to the 
enhancement of the transport of low molecular weight permeability markers that may be due to 
the opening the TJ of the brain endothelial cells, an increase in the formation of small pores at the 
BBB, or combination of both permeation pathways. A larger sample size is needed to confirm the 
initial in situ perfusion study results and then to determine the mechanism responsible for 





A.5 Reference  
 
1. Zheng, K.; Trivedi, M.; Siahaan, T. J., Structure and function of the intercellular 
junctions: barrier of paracellular drug delivery. Curr. Pharm. Des. 2006, 12 (22), 2813-
24. 
2. Abbott, N. J.; Friedman, A., Overview and introduction: the blood-brain barrier in health 
and disease. Epilepsia 2012, 53 Suppl 6, 1-6. 
3. Abbott, N. J.; Rönnbäck, L.; Hansson, E., Astrocyte-endothelial interactions at the blood-
brain barrier. Nature Reviews Neuroscience 2006, 7 (1), 41-53. 
4. Schmitt, G.; Parrott, N.; Prinssen, E.; Barrow, P., The great barrier belief: The blood–
brain barrier and considerations for juvenile toxicity studies. Reprod. Toxicol. 
5. Persidsky, Y.; Ramirez, S. H.; Haorah, J.; Kanmogne, G. D., Blood–brain barrier: 
structural components and function under physiologic and pathologic conditions. J. 
Neuroimmune Pharmacol. 2006, 1 (3), 223-236. 
6. Pardridge, W. M., Transport of small molecules through the blood-brain barrier: biology 
and methodology. Adv. Drug Del. Rev. 1995, 15 (1), 5-36. 
7. Davis, T. P.; Abbruscato, T. J.; Egleton, R. D., Peptides at the blood brain barrier: 
Knowing me knowing you. Peptides 2015, 72, 50-56. 
8. Laksitorini, M. D.; Kiptoo, P. K.; On, N. H.; Thliveris, J. A.; Miller, D. W.; Siahaan, T. 
J., Modulation of Intercellular Junctions by Cyclic-ADT Peptides as a Method to 
Reversibly Increase Blood-Brain Barrier Permeability. J. Pharm. Sci. 2015, 104 (3), 
1065-1075. 
9. Abbott, N. J., Astrocyte-endothelial interactions and blood-brain barrier permeability. J. 
Anat. 2002, 200 (6), 629-38. 
10. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J., Structure 
and function of the blood–brain barrier. Neurobiol. Dis. 2010, 37 (1), 13-25. 
11. Kuhnline Sloan, C. D.; Nandi, P.; Linz, T. H.; Aldrich, J. V.; Audus, K. L.; Lunte, S. M., 
Analytical and biological methods for probing the blood-brain barrier. Annu. Rev. Anal. 
Chem. (Palo Alto Calif.) 2012, 5, 505-31. 
12. Sandoval, K. E.; Witt, K. A., Blood-brain barrier tight junction permeability and ischemic 
stroke. Neurobiol. Dis. 2008, 32 (2), 200-219. 
188 
 
13. Minagar, A.; Alexander, J. S., Blood-brain barrier disruption in multiple sclerosis. Mult. 
Scler. 2003, 9 (6), 540-9. 
14. Buckner, C. M.; Luers, A. J.; Calderon, T. M.; Eugenin, E. A.; Berman, J. W., 
Neuroimmunity and the Blood–Brain Barrier: Molecular Regulation of Leukocyte 
Transmigration and Viral Entry into the Nervous System with a Focus on NeuroAIDS. J. 
Neuroimmune Pharmacol. 2006, 1 (2), 160-181. 
15. Martin, T. A.; Jiang, W. G., Loss of tight junction barrier function and its role in cancer 
metastasis. Biochim. Biophys. Acta 2009, 1788 (4), 872-891. 
16. Stamatovic, S. M.; Keep, R. F.; Andjelkovic, A. V., Brain Endothelial Cell-Cell 
Junctions: How to “Open” the Blood Brain Barrier. Curr. Neuropharmacol. 2008, 6 (3), 
179-192. 
17. Pardridge, W. M., The Blood-Brain Barrier: Bottleneck in Brain Drug Development. 
NeuroRx 2005, 2 (1), 3-14. 
18. Tanaka, H.; Mizojiri, K., Drug-Protein Binding and Blood-Brain Barrier Permeability. J. 
Pharmacol. Exp. Ther. 1999, 288 (3), 912-918. 
19. Pardridge, W. M., Drug transport across the blood–brain barrier. J. Cereb. Blood Flow 
Metab. 2012, 32 (11), 1959-1972. 
20. Hervé, F.; Ghinea, N.; Scherrmann, J.-M., CNS Delivery Via Adsorptive Transcytosis. 
The AAPS Journal 2008, 10 (3), 455-472. 
21. Tsuji, A.; Tamai, I., Carrier-mediated or specialized transport of drugs across the blood–
brain barrier. Adv. Drug Del. Rev. 1999, 36 (2), 277-290. 
22. Banks, W. A.; Jaspan, J. B.; Huang, W.; Kastin, A. J., Transport of Insulin Across the 
Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin. Peptides 1997, 18 (9), 
1423-1429. 
23. Jones, A. R.; Shusta, E. V., Blood-Brain Barrier Transport of Therapeutics via Receptor-
Mediation. Pharm. Res. 2007, 24 (9), 1759-1771. 
24. McAllister, M. S.; Krizanac-Bengez, L.; Macchia, F.; Naftalin, R. J.; Pedley, K. C.; 
Mayberg, M. R.; Marroni, M.; Leaman, S.; Stanness, K. A.; Janigro, D., Mechanisms of 




25. Spector, R.; Johanson, C. E., REVIEW: Vitamin transport and homeostasis in 
mammalian brain: focus on Vitamins B and E. J. Neurochem. 2007, 103 (2), 425-438. 
26. Gardiner, R. M., Transport of amino acids across the blood-brain barrier: implications for 
treatment of maternal phenylketonuria. J. Inherit. Metab. Dis. 1990, 13 (4), 627-33. 
27. Deng, D.; Xu, C.; Sun, P.; Wu, J.; Yan, C.; Hu, M.; Yan, N., Crystal structure of the 
human glucose transporter GLUT1. Nature 2014, 510 (7503), 121-125. 
28. Brasnjevic, I.; Steinbusch, H. W. M.; Schmitz, C.; Martinez-Martinez, P., Delivery of 
peptide and protein drugs over the blood–brain barrier. Prog. Neurobiol. 2009, 87 (4), 
212-251. 
29. Sánchez-Navarro, M.; Giralt, E.; Teixidó, M., Blood–brain barrier peptide shuttles. Curr. 
Opin. Chem. Biol. 2017, 38, 134-140. 
30. Audus, K. L.; Borchardt, R. T., Bovine brain microvessel endothelial cell monolayers as 
a model system for the blood-brain barrier. Ann. N. Y. Acad. Sci. 1987, 507, 9-18. 
31. Helms, H. C.; Abbott, N. J.; Burek, M.; Cecchelli, R.; Couraud, P. O.; Deli, M. A.; 
Forster, C.; Galla, H. J.; Romero, I. A.; Shusta, E. V.; Stebbins, M. J.; Vandenhaute, E.; 
Weksler, B.; Brodin, B., In vitro models of the blood-brain barrier: An overview of 
commonly used brain endothelial cell culture models and guidelines for their use. J. 
Cereb. Blood Flow Metab. 2016, 36 (5), 862-90. 
32. Bickel, U., How to measure drug transport across the blood-brain barrier. NeuroRx 2005, 
2 (1), 15-26. 
33. He, Y.; Yao, Y.; Tsirka, S. E.; Cao, Y., Cell-Culture Models of the Blood–Brain Barrier. 
Stroke; a journal of cerebral circulation 2014, 45 (8), 2514-2526. 
34. Ruck, T.; Bittner, S.; Meuth, S. G., Blood-brain barrier modeling: challenges and 
perspectives. Neural Regeneration Research 2015, 10 (6), 889-891. 
35. Smith, Q. R., A Review of Blood-Brain Barrier Transport Techniques. In The Blood-
Brain Barrier: Biology and Research Protocols, Nag, S., Ed. Humana Press: Totowa, NJ, 
2003; pp 193-208. 
36. Takasato, Y.; Rapoport, S. I.; Smith, Q. R., An in situ brain perfusion technique to study 
cerebrovascular transport in the rat. American Journal of Physiology - Heart and 
Circulatory Physiology 1984, 247 (3), H484-H493. 
190 
 
37. Bartels, A. L.; Willemsen, A. T.; Kortekaas, R.; de Jong, B. M.; de Vries, R.; de Klerk, 
O.; van Oostrom, J. C.; Portman, A.; Leenders, K. L., Decreased blood-brain barrier P-
glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural 
Transm (Vienna) 2008, 115 (7), 1001-9. 
38. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P.-O., The blood-brain barrier in brain 
homeostasis and neurological diseases. Biochim. Biophys. Acta 2009, 1788 (4), 842-857. 
39. Ivey, N. S.; MacLean, A. G.; Lackner, A. A., AIDS and the blood-brain barrier. J. 
Neurovirol. 2009, 15 (2), 111-122. 
40. Morrey, J. D.; Olsen, A. L.; Siddharthan, V.; Motter, N. E.; Wang, H.; Taro, B. S.; Chen, 
D.; Ruffner, D.; Hall, J. O., Increased blood-brain barrier permeability is not a primary 
determinant for lethality of West Nile virus infection in rodents. J. Gen. Virol. 2008, 89 
(Pt 2), 467-73. 
41. Kaya, M.; Ahishali, B., Assessment of permeability in barrier type of endothelium in 
brain using tracers: Evans blue, sodium fluorescein, and horseradish peroxidase. Methods 
Mol. Biol. 2011, 763, 369-82. 
42. Ziylan, Y. Z.; Robinson, P. J.; Rapoport, S. I., Differential blood-brain barrier 
permeabilities to [14C]sucrose and [3H]inulin after osmotic opening in the rat. Exp. 
Neurol. 1983, 79 (3), 845-57. 
43. Saunders, N. R.; Dziegielewska, K. M.; Mollgard, K.; Habgood, M. D., Markers for 
blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century 
and what are the alternatives? Front. Neurosci. 2015, 9, 385. 
44. Sloan, C. D. K.; Audus, K. L.; Aldrich, J. V.; Lunte, S. M., The permeation of dynorphin 
A 1–6 across the blood brain barrier and its effect on bovine brain microvessel 
endothelial cell monolayer permeability. Peptides 2012, 38 (2), 414-417. 
45. Thompson, S. E.; Audus, K. L., Leucine enkephalin effects on brain microvessel 
endothelial cell monolayer permeability. Pharm. Res. 1994, 11 (9), 1366-9. 
46. Thompson, S. E.; Cavitt, J.; Audus, K. L., Leucine enkephalin effects on paracellular and 
transcellular permeation pathways across brain microvessel endothelial cell monolayers. 
J. Cardiovasc. Pharmacol. 1994, 24 (5), 818-25. 
 
 
 
